[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 285
1. Nakayama T, Ling ZQ, Mukaisho K, Hattori T, Sugihara H: Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous? BMC Cancer; 2010;10:311
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous?
  • BACKGROUND: Eradication of early gastric carcinoma (GC) is thought to contribute to reduction in the mortality of GC, given that most of the early GCs progress to the advanced GCs.
  • The aim of this study was to clarify the extent of overlap of genetic lineages between early and advanced tubular adenocarcinomas (TUBs) of the stomach.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Lineage / genetics. Proto-Oncogene Proteins c-myc / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1987;15(1):14-7 [3561327.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):311-8 [3791218.001]
  • [Cites] Lancet. 1991 Feb 9;337(8737):344-6 [1671243.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4798-804 [8062281.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):299-305 [10092127.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Genet. 2004 Sep;115(4):327-30 [15290239.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):156-66 [15796963.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):285-91 [16078225.001]
  • [Cites] Genomics. 2006 Feb;87(2):298-306 [16271290.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Pathobiology. 2006;73(1):40-9 [16785766.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6469-79 [17085661.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):214-21 [18000373.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):97-103 [10704677.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Apr 15;118(2):99-107 [10748289.001]
  • [Cites] Gut. 2000 Nov;47(5):618-21 [11034575.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):27-34 [11120330.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):31-8 [11213833.001]
  • [Cites] Jpn J Cancer Res. 2001 Jul;92(7):740-7 [11473724.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 1;132(1):30-5 [11801305.001]
  • [Cites] J Pathol. 2003 Nov;201(3):371-6 [14595748.001]
  • [Cites] J Pathol. 2003 Nov;201(3):439-50 [14595756.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):1001-8 [14707283.001]
  • [Cites] J Pathol. 2004 Aug;203(4):884-95 [15258990.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1223-34 [15154009.001]
  • [Cites] Pathol Annu. 1980;15(Pt 2):1-19 [6256703.001]
  • [Cites] Int J Cancer. 1983 Apr 15;31(4):421-6 [6832853.001]
  • [Cites] Lancet. 1984 Aug 4;2(8397):271-3 [6146820.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(2):117-27 [3037769.001]
  • (PMID = 20565940.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2898698
  •  go-up   go-down


2. Wei M, Morimura K, Wanibuchi H, Shen J, Salim EI, Moku M, Hakoi K, Fukushima S: JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats. Int J Cancer; 2005 Jan 20;113(3):354-8
Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
  • Forty weeks after the start of the experiment, administration of 150 ppm JTE-522 during both initiation and postinitiation stages significantly inhibited the incidences of tubular adenocarcinomas and total carcinomas, as well as total tumors in the colon.
  • The inhibitory effect of JTE-522 was most prominent for tubular adenocarcinomas, but was not observed in the nontubular carcinomas (signet-ring cell and mucinous carcinomas).
  • Almost equal inhibitory effects on tubular adenocarcinomas were also observed in the rats given 150 ppm JTE-522 during the postinitiation stage, suggesting that its major anticancer action is at the postinitiation phase.
  • However, JTE-522 had no effect on the size or invasive extent of tubular adenocarcinomas.
  • Furthermore, microarray analyses revealed that JTE-522 had no effect on gene expression levels in DMH-induced tubular adenocarcinomas.
  • These findings suggest that JTE-522 possesses chemopreventive activity against induction but not progression of tubular adenocarcinomas in rat colon.
  • In view of the significant inhibitory effects of JTE-522 on ACF, its major anticancer action may occur in the postinitiation stage but before the malignant conversion stage of DMH-induced colon carcinogenesis.
  • [MeSH-major] 1,2-Dimethylhydrazine / toxicity. Adenocarcinoma / prevention & control. Benzenesulfonates / therapeutic use. Carcinogens / toxicity. Colonic Neoplasms / prevention & control. Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors. Oxazoles / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455344.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; 0 / Benzenesulfonates; 0 / Biomarkers, Tumor; 0 / Carcinogens; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Oxazoles; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


3. Hirano Y, Hara T, Nozawa H, Oyama K, Ohta N, Omura K, Watanabe G, Niwa H: Combined choriocarcinoma, neuroendocrine cell carcinoma and tubular adenocarcinoma in the stomach. World J Gastroenterol; 2008 May 28;14(20):3269-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined choriocarcinoma, neuroendocrine cell carcinoma and tubular adenocarcinoma in the stomach.
  • We described a patient with adenocarcinoma of the stomach combined with choriocarcinoma and neuroendocrine cell carcinoma.
  • Choriocarcinoma, small cell carcinoma and tubular adenocarcinoma existed in the gastric tumor.
  • The small cell carcinomatous foci contained cells positive for synaptophysin, neuron-specific enolase (NSE), and chromogranin A.
  • The prognosis for gastric adenocarcinoma with choriocarcinoma and neuroendocrine cell carcinoma is exceedingly poor.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Choriocarcinoma / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / pathology


Advertisement
4. Kunju LP, Ding Y, Kleer CG: Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions. Pathol Int; 2008 Oct;58(10):620-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
  • The distinction between tubular carcinomas (TC) and invasive well-differentiated (grade 1) ductal carcinoma (IDC) is important given treatment and prognostic differences.
  • Of 14 TC, eight (57%) had associated FEA, seven (50%) had micropapillary atypical ductal hyperplasia (ADH), three (21%) had low nuclear grade ductal carcinoma in situ (DCIS), and four (29%) had lobular neoplasia.
  • All tubular carcinomas were estrogen receptor (ER) positive and negative for Her-2/neu overexpression.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801081.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / R01 CA125577; United States / NCI NIH HHS / CA / CA090876; United States / NCI NIH HHS / CA / CA107469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


5. Zandrino F, Calabrese M, Faedda C, Musante F: Tubular carcinoma of the breast: pathological, clinical, and ultrasonographic findings. A review of the literature. Radiol Med; 2006 Sep;111(6):773-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: pathological, clinical, and ultrasonographic findings. A review of the literature.
  • PURPOSE: Tubular carcinoma of the breast is a well-differentiated adenocarcinoma.
  • MATERIALS AND METHODS: A retrospective review of 560 consecutive histologically proven carcinomas of the breast was made.
  • RESULTS: Sixteen pure (tubular component >90%) tubular carcinomas were found in 14 women (mean age 55 years).
  • Fine-needle aspiration cytology diagnosed 11 carcinomas and two "atypical cells".
  • In three, core biopsy was made: in the first, a complex sclerosing lesion with atypical cells was suggested, in the second differential diagnosis between tubular carcinoma and sclerosing adenosis was proposed and in the third a tubular carcinoma.
  • CONCLUSIONS: Tubular carcinoma presents as a small, nonpalpable lesion, with nonspecific imaging patterns.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896563.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


6. Shin HJ, Kim HH, Kim SM, Kim DB, Lee YR, Kim MJ, Gong G: Pure and mixed tubular carcinoma of the breast: mammographic and sonographic differential features. Korean J Radiol; 2007 Mar-Apr;8(2):103-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure and mixed tubular carcinoma of the breast: mammographic and sonographic differential features.
  • OBJECTIVE: We wanted to evaluate the mammographic and sonographic differential features between pure (PT) and mixed tubular carcinoma (MT) of the breast.
  • However, the absence of a mass on mammography or the presence of an oval shaped mass would favor the diagnosis of PT.
  • An irregularly shaped mass with surrounding tissue change and posterior shadowing on sonography would favor the diagnosis of MT and also a less favorable prognosis.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / ultrasonography. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jan;174(1):253-7 [10628489.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):319-23 [9930775.001]
  • [Cites] Am J Clin Pathol. 1978 Aug;70(2):204-10 [696679.001]
  • [Cites] Radiology. 1978 Nov;129(2):311-4 [212776.001]
  • [Cites] Cancer. 1978 Nov;42(5):2334-42 [214219.001]
  • [Cites] Am J Clin Pathol. 1980 Jan;73(1):25-30 [6243440.001]
  • [Cites] Am J Surg Pathol. 1979 Oct;3(5):387-95 [532858.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):138-49 [7469549.001]
  • [Cites] Am J Clin Pathol. 1982 Jul;78(1):1-7 [6285690.001]
  • [Cites] Am J Surg Pathol. 1982 Jul;6(5):401-11 [6289683.001]
  • [Cites] Histopathology. 1985 Mar;9(3):271-80 [2987100.001]
  • [Cites] Radiology. 1989 Dec;173(3):697-700 [2554361.001]
  • [Cites] AJR Am J Roentgenol. 1993 Feb;160(2):263-5 [8424330.001]
  • [Cites] Acta Radiol. 1993 Jan;34(1):43-7 [8427748.001]
  • [Cites] AJR Am J Roentgenol. 1993 Dec;161(6):1173-6 [8249721.001]
  • [Cites] Am Surg. 1997 Jul;63(7):639-44; discussion 644-5 [9202540.001]
  • [Cites] Am J Clin Pathol. 1972 Sep;58(3):231-8 [4342376.001]
  • (PMID = 17420627.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2626773
  •  go-up   go-down


7. Abdul Aziz M, Sullivan F, Kerin MJ, Callagy G: Malignant phyllodes tumour with liposarcomatous differentiation, invasive tubular carcinoma, and ductal and lobular carcinoma in situ: case report and review of the literature. Patholog Res Int; 2010;2010:501274
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumour with liposarcomatous differentiation, invasive tubular carcinoma, and ductal and lobular carcinoma in situ: case report and review of the literature.
  • Histology revealed a malignant phyllodes tumour (PT) with liposarcomatous differentiation and ductal carcinoma in situ (DCIS) within the tumour with invasive tubular carcinoma, DCIS, and lobular carcinoma in situ in the surrounding breast.
  • Liposarcomatous differentiation is uncommon in PTs, and coexisting carcinoma is rare with 38 cases in 31 reports in the literature.
  • Carcinoma is reported in malignant (n = 19), benign (n = 16) and in borderline PTs (n = 3) with invasive carcinoma (n = 18) and pure in situ carcinoma (n = 19) recorded in equal frequency.
  • Carcinoma is more commonly found within the confines of benign PTs; whereas it is more often found surrounding the PT or in the contralateral breast in malignant PTs.
  • The aetiology of co-existing carcinoma is unclear but the rarity of previous radiotherapy treatment suggests that it is incidental.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151726.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990446
  •  go-up   go-down


8. Oh DK, Kim SH, Choi SH, Jang KT: Intraductal tubular carcinoma of the pancreas: a case report with the imaging findings. Korean J Radiol; 2008 Sep-Oct;9(5):473-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular carcinoma of the pancreas: a case report with the imaging findings.
  • We describe here a case of intraductal tubular carcinoma of the main pancreatic duct.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):233-8 [15043313.001]
  • [Cites] Pancreas. 2004 Aug;29(2):116-22 [15257103.001]
  • [Cites] Am J Gastroenterol. 1996 Apr;91(4):798-800 [8677955.001]
  • [Cites] Pancreas. 2005 Mar;30(2):115-21 [15714133.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):325-9 [15729258.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):702-5 [16933009.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Nov;30(11):1301-4 [17185972.001]
  • [Cites] Pathol Int. 2007 Nov;57(11):741-5 [17922686.001]
  • (PMID = 18838860.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2627216
  •  go-up   go-down


9. Sullivan T, Raad RA, Goldberg S, Assaad SI, Gadd M, Smith BL, Powell SN, Taghian AG: Tubular carcinoma of the breast: a retrospective analysis and review of the literature. Breast Cancer Res Treat; 2005 Oct;93(3):199-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: a retrospective analysis and review of the literature.
  • BACKGROUND: The favorable prognosis associated with tubular carcinoma of the breast has led some studies to propose less aggressive treatments for patients with this disease.
  • This study aims to address the extent of therapy needed for tubular patients.
  • METHODS: A retrospective review identified 73 cases of tubular carcinoma treated at the Massachusetts General Hospital between 1980 and 2002.
  • Primary treatment was conservative surgery (CS) plus radiation therapy (RT) in 67%, CS without RT in 18%, and mastectomy in 15%.
  • The published literature of 529 conservatively treated tubular carcinomas was reviewed along with the 62 conservative cases from this series.
  • All three had initially been treated with CS + RT.
  • Thirteen women, with a median age of 74, were treated by CS without RT and none recurred.
  • A literature review showed that adjuvant RT reduces local failure following CS for tubular carcinoma.
  • CONCLUSIONS: Tubular carcinoma is associated with an excellent prognosis, but long-term follow-up is essential for detecting local failures and a small primary tumor size does not preclude nodal involvement.
  • Adjuvant RT reduces the incidence of local failure following CS for tubular carcinoma, however, elderly women treated by CS may have a very low risk of local recurrence without adjuvant RT.
  • [MeSH-major] Adenocarcinoma / surgery. Breast Neoplasms / surgery. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142444.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 45
  •  go-up   go-down


10. Fernández-Aguilar S, Simon P, Buxant F, Fayt I, Nöel JC: Is complete axillary lymph node dissection neccessary in T1 stage invasive pure tubular carcinomas of the breast? Breast; 2005 Aug;14(4):325-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is complete axillary lymph node dissection neccessary in T1 stage invasive pure tubular carcinomas of the breast?
  • The purpose of this study was to evaluate the frequency of axillary lymph node metastasis in invasive pure (not mixed) tubular carcinomas of the breast and to compare our results to other series published in the literature.
  • We analyzed 16 cases of pure tubular carcinoma measuring 2 cm or less in diameter from our database from 1988 to 2004 diagnosed in lumpectomy and mastectomy specimens with associated axillary lymph node dissection.
  • These data slightly differ from the results of some studies recently published in the literature, in which the overall nodal involvement in pure tubular carcinomas ranges from 0% to 20%.
  • We conclude that in invasive pure tubular carcinomas of the breast measuring less than 2 cm in diameter, complete axillary lymph node dissection should be avoided, and we propose a sentinel lymph node analysis instead.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085240.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


11. Sawai T, Inoue Y, Doi S, Ikuta Y, Kimino K, Nakashima M, Soda H, Kohno S: Tubular adenocarcinoma of the thymus: case report and review of the literature. Int J Surg Pathol; 2006 Jul;14(3):243-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular adenocarcinoma of the thymus: case report and review of the literature.
  • Primary carcinomas of the thymus are rare.
  • A variety of histologic patterns have been reported, and the most common are squamous cell carcinoma, lymphoepithelioma like carcinoma, and basaloid carcinoma.
  • Adenocarcinomas of the thymus are extremely rare.
  • As determined from a literature search, a pure tubular adenocarcinoma has never been previously described, and thus, this is first case report of tubular adenocarcinoma of the thymus.
  • [MeSH-major] Adenocarcinoma / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959713.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


12. Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW: HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol; 2006 Jul;126(1):55-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 amplification in tubular carcinoma of the breast.
  • To address the relative paucity of information concerning HER-2 amplification for tubular carcinomas, we assessed the frequency of gene amplification in 55 tubular carcinomas of the breast from 54 patients, 5 of which had axillary node metastases.
  • This HER-2 gene amplification frequency was significantly lower than the frequency of gene amplification previously reported for all invasive ductal carcinoma of no special type (P < .01).
  • HER-2 gene amplification likely occurs infrequently, or not at all, in tubular carcinomas of the breast, whereas most express estrogen receptors.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Gene Amplification. Genes, erbB-2. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753605.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


13. Fedko MG, Scow JS, Shah SS, Reynolds C, Degnim AC, Jakub JW, Boughey JC: Pure tubular carcinoma and axillary nodal metastases. Ann Surg Oncol; 2010 Oct;17 Suppl 3:338-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure tubular carcinoma and axillary nodal metastases.
  • BACKGROUND: Pure tubular carcinoma of the breast is a rare subtype with a low incidence of axillary lymph node metastases.
  • The aim of this study was to determine the frequency of axillary lymph node metastasis in patients with pure tubular carcinoma.
  • METHODS: We identified patients diagnosed with tubular carcinoma from 1987 to 2009 from our institution's tumor registry.
  • Pathology slides were reviewed, and pure tubular carcinoma was defined as ≥ 90% tubule formation, low nuclear grade, and rare to no mitoses.
  • RESULTS: We identified 105 cases of pure tubular carcinoma of the breast in 103 patients.
  • CONCLUSIONS: Axillary lymph node metastases are not common in small pure tubular carcinomas.
  • Nodal staging may be omitted in small pure tubular carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853056.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sahoo S, Recant WM: Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast. Breast J; 2005 Mar-Apr;11(2):140-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
  • Columnar cell alteration in the breast encompasses a spectrum of pathologic changes ranging from simple columnar cell change to more complex columnar cell hyperplasia with and without atypia to in situ carcinoma, often with a micropapillary architecture.
  • For reasons that remain unclear, the columnar cell lesions are associated with tubular carcinomas and lobular carcinoma in situ.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Breast / pathology. Calcinosis / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730461.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP: Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol; 2009 Nov;33(11):1646-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
  • Low-grade precursor lesions, such flat epithelial atypia (FEA), low-grade ductal carcinoma in situ (lg-DCIS), and lobular neoplasia (LN) often coexist with invasive tubular carcinomas (TCs) of the breast.
  • In these lesions (22 FEA, 10 lg-DCIS, 3 LN), loss of heterozygosity was most frequently observed on the long arm of chromosome 16 as well as at chromosome 8p21, 3p14, 1p36 and 11q14 with a high degree of homology of allelic losses between FEA, lg-DCIS and tubular carcinomas.
  • In the adjacent invasive tubular carcinomas, mitochondrial DNA sequencing revealed identical mutation patterns in 50% of the lg-DCIS and in 12 of 21 (57%) informative cases of FEA.
  • No direct association was seen between TC and LN or columnar cell lesions without nuclear atypia.
  • Our data indicate, that in the majority of cases lg-DCIS and FEA are directly related to tubular breast cancer with a possible precursor role.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675453.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


16. Bareggi C, Consonni D, Galassi B, Gambini D, Locatelli E, Visintin R, Runza L, Giroda M, Reali G, Tomirotti M: Uncommon breast malignancies: Presentation pattern, treatment options and outcome in a single Institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e22174

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Rare subtypes were represented as follows: tubular 2.7% (58 pts), mucinous 1.1% (25 pts), medullary 1% (21 pts), papillary 0.4% (8 pts).
  • Median age at diagnosis was 56.5 years among patients with tubular histotype, 68.9 years for mucinous, 55 and 61.7 years for medullary and papillary, respectively.
  • Stage I tumors were 87.7% among patients with tubular differentiation, 60% for mucinous, 26.3% for medullary and 50% for papillary, (compared to 45.7% in invasive ductal carcinoma: 1,626 pts).
  • Stage II represented 12.3% among patients with tubular carcinoma, 32% for mucinous, 57.9% for medullary and 37.5% for papillary.
  • Median DFS for patients with tubular cancer was 4.1 years, for mucinous 3.7 years, 10.5 and 5.1 years for medullary and papillary, respectively.
  • Median OS for patients with tubular cancer was 4.3 years, whereas for mucinous 4.2 years, for medullary 11 years and 5.3 years for papillary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963710.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous or tubular carcinoma was frequently seen in the Luminal A type.
  • Squamous cell, spindle cell carcinoma, or metaplastic carcinoma with bone/cartilage metaplasia was found in only TN type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Günhan-Bilgen I, Oktay A: Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings. Eur J Radiol; 2007 Jan;61(1):158-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings.
  • PURPOSE: To determine and quantitate the radiological characteristics of tubular carcinoma of the breast, to report clinical and pathologic findings and to define findings at follow-up.
  • MATERIALS AND METHODS: A retrospective review of records of 2872 women who received a diagnosis of breast carcinoma between January 1988 and January 2006 revealed 32 histopathologically proven pure tubular carcinoma of the breast.
  • Analysis included history; findings at physical examination, mammography, and sonography (US) at the time of diagnosis and in postoperative follow-up and histopathological results.
  • Four (13%) patients developed contralateral breast carcinoma at follow-up.
  • CONCLUSION: Tubular carcinoma has a variety of presentations, but it is mostly seen on mammography as a small spiculated mass, and on sonography as an irregular mass with posterior acoustic shadowing.
  • Although tubular carcinoma is known as a well-differentiated tumor with excellent prognosis, the mammographic follow-up of the contralateral breast is important.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / ultrasonography. Breast Neoplasms / epidemiology. Breast Neoplasms / ultrasonography. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / ultrasonography. Ultrasonography, Mammary / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16987629.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


19. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Alvarenga M, Vassallo J: p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):71-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?
  • The immunohistochemical detection of myoepithelial cells in benign sclerosing lesions of the breast is useful in distinguishing them from tubular carcinoma.
  • The authors assessed the use of p63 and CD10 in the differential diagnosis between benign sclerosing lesions, such as sclerosing adenosis and radial scar, and tubular carcinoma, in comparison to the traditional myoepithelial markers 1A4 and calponin. p63, CD10, 1A4, and calponin were expressed in myoepithelial cells of all benign lesions and were consistently negative in all cases of tubular carcinoma.
  • In conclusion, p63 and CD10 may be used as a complement to 1A4 in distinguishing benign sclerosing lesions from tubular carcinoma of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540734.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


20. Lopez-Garcia MA, Geyer FC, Natrajan R, Kreike B, Mackay A, Grigoriadis A, Reis-Filho JS, Weigelt B: Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol; 2010 Sep;222(1):64-75
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas.
  • Tubular carcinoma (TC) is an uncommon special type of breast cancer characterized by an indolent clinical course.
  • Although described as part of a spectrum of related lesions named 'low-grade breast neoplasia family' due to immunophenotypical and genetic similarities, TCs, low-grade invasive ductal carcinomas of no special type (IDC-NSTs), and classic invasive lobular carcinomas (ILCs) significantly differ in terms of histological features and clinical outcome.
  • Transcriptomic differences between TCs and molecular subtype-matched classic ILCs were more overt, predominantly due to lower expression of proliferation and cell cycle genes in TCs and down-regulation of cell adhesion/extracellular matrix-related genes in classic ILCs.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593406.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Livi L, Paiar F, Meldolesi E, Talamonti C, Simontacchi G, Detti B, Salerno S, Bianchi S, Cardona G, Biti GP: Tubular carcinoma of the breast: outcome and loco-regional recurrence in 307 patients. Eur J Surg Oncol; 2005 Feb;31(1):9-12
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: outcome and loco-regional recurrence in 307 patients.
  • PURPOSE: The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma.
  • MATERIAL AND METHODS: Three hundred and seven patients (median age 56.4 years, range 26-91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001.
  • [MeSH-major] Adenocarcinoma / therapy. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642419.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


22. Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, Macmillan D, Blamey RW, Ellis IO: Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol; 2010 Jan 1;28(1):99-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: further evidence to support its excellent prognosis.
  • PURPOSE Although tubular carcinoma (TC) is known to have a favorable prognosis, it is still unknown whether this subtype represents a distinct type of breast carcinoma or whether it behaves like other low-grade luminal A-type breast carcinomas.
  • METHODS In this study, we performed a retrospective analysis of a large well-characterized series of breast cancers (2,608 carcinomas) to assess the clinicopathologic and molecular features and prognostic value of TC compared with grade 1 ductal carcinomas of the breast.
  • Results When compared with grade 1 ductal carcinoma (n = 212), TC (n = 102) was more likely to be detected on mammographic screening, had smaller median size, and less frequently showed lymphovascular invasion.
  • Compared with grade 1 ductal carcinoma, TC was associated with longer disease-free survival (chi(2) = 13.25, P < .001) and breast cancer-specific survival (chi(2) = 8.8, P = .003).
  • In this study, none of the patients with TC developed distant metastasis or died from the disease without an intervening recurrence as invasive carcinoma of different histologic type.
  • CONCLUSION We conclude that the biologic behavior of TC is excellent and is more favorable than that of grade 1 ductal carcinoma.
  • Patients with TC may be at risk of developing second primary carcinomas in the contralateral breast, which may be of higher grade and poorer potential prognostic outcome.
  • [MeSH-major] Adenocarcinoma / mortality. Breast Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917872.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Fernandez-Aguilar S, Noël JC: Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast. APMIS; 2008 Jan;116(1):33-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast.
  • Tubular carcinoma (TC) is a distinctive type of grade I (G1) ductal carcinoma with particularly favourable outcome and low rate of axillary metastases.
  • To the best of our knowledge, few data are available in the literature concerning the expression of molecules mediating intercellular and cell-matrix interactions in TC.
  • We examined with immunohistochemical methods the expression of galectin 3 and cathepsin D in 17 TC and in 33, 31 and 28 ductal carcinomas of G1, grade II (G2) and grade III (G3), respectively.
  • Galectin 3 expression was higher in TC than in G1 carcinomas (p<0.05).
  • The higher expression of galectin 3 in TC and its focal staining (apical) pattern suggests that within the group of G1 carcinomas, galectin 3 expression varies according to histological type, and may correlate with prognosis and metastatic potential.
  • We also suggest that cathepsin D could not be involved in neoplastic progression and metastasis in low-grade (G1) ductal breast carcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast / metabolism. Carcinoma, Ductal, Breast / metabolism. Cathepsin D / metabolism. Galectin 3 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254778.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Galectin 3; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


24. Liu GF, Yang Q, Haffty BG, Moran MS: Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1304-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy.
  • PURPOSE: To evaluate our institutional experience of treating tubular carcinoma of the breast (TC) and invasive ductal carcinoma (IDC) with conservative surgery and radiation therapy, to compare clinical-pathologic features and long-term outcomes.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386432.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. García N, Ramis G, Pallarés FJ, Seva JI, Martínez CM, Quereda JJ, Muñoz A: Clinical, histologic, and immunohistochemical features of an undifferentiated renal tubular carcinoma in a juvenile olive baboon (Papio anubis). J Vet Diagn Invest; 2009 Jul;21(4):535-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, histologic, and immunohistochemical features of an undifferentiated renal tubular carcinoma in a juvenile olive baboon (Papio anubis).
  • An undifferentiated renal tubular carcinoma was diagnosed in a juvenile male olive baboon (Papio anubis).
  • The neoplasm was diagnosed as an undifferentiated renal tubular carcinoma.
  • [MeSH-major] Carcinoma / veterinary. Kidney Neoplasms / veterinary. Monkey Diseases / pathology. Papio anubis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564506.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hioki M, Nakagohri T, Ikumoto T, Gotohda N, Takahashi S, Konishi M, Kojima M, Kinoshita T: Intraductal tubular carcinoma of the pancreas: case report with review of literature. Anticancer Res; 2010 Nov;30(11):4435-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular carcinoma of the pancreas: case report with review of literature.
  • Intraductal tubular carcinoma (ITC) was diagnosed by immunohistochemical staining and electron microscopic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115890.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


27. Javid SH, Smith BL, Mayer E, Bellon J, Murphy CD, Lipsitz S, Golshan M: Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg; 2009 May;197(5):674-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: results of a large contemporary series.
  • BACKGROUND: Tubular carcinoma (TC) of the breast is an uncommon subtype associated with a favorable prognosis.
  • The median patient age at diagnosis was 55 years, and the median follow-up period was 72 months.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789411.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Fernandez-Aguilar S, Jondet M, Simonart T, Nöel JC: Microvessel and lymphatic density in tubular carcinoma of the breast: comparative study with invasive low-grade ductal carcinoma. Breast; 2006 Dec;15(6):782-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvessel and lymphatic density in tubular carcinoma of the breast: comparative study with invasive low-grade ductal carcinoma.
  • Tubular carcinoma (TC) of the breast is an uncommon variant of ductal carcinoma, which has an extremely low metastatic potential and an excellent prognosis.
  • We compared the results with those observed in 30 low-grade ductal breast carcinomas (LGDC) of no specific type with similar dimensions.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / pathology. Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / blood supply. Carcinoma, Ductal, Breast / pathology. Lymphatic Vessels / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931017.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / monoclonal antibody D2-40
  •  go-up   go-down


29. Nozawa H, Yamada Y, Muto Y, Endo J, Asakage M, Oka T, Furukawa Y, Arai M: Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report. Eur J Gastroenterol Hepatol; 2010 Feb;22(2):228-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report.
  • Biopsied lung tumor was diagnosed as tubular adenocarcinoma, and CK7(+)/CK20(+)/Cdx-2(-).
  • Together with clinical information, we deduced that the jejunal adenocarcinoma had presumably metastasized to the lung.
  • Moreover, postoperative oxaliplatin, including chemotherapy, significantly reduced the lung metastases, suggesting that this regimen is a promising treatment option for advanced small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Colonic Neoplasms / pathology. Immunohistochemistry. Jejunal Neoplasms / pathology. Lung Neoplasms / secondary. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19923997.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


30. Leonard CE, Howell K, Shapiro H, Ponce J, Kercher J: Excision only for tubular carcinoma of the breast. Breast J; 2005 Mar-Apr;11(2):129-33
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excision only for tubular carcinoma of the breast.
  • The purpose of this study was to assess the rationale of excision only (without breast irradiation) in patients with small (< or =3 cm) tubular/well-differentiated breast cancers.
  • A total of 44 patients with pure tubular invasive breast cancer who have undergone complete excision only and have had a minimum 1-year follow-up were identified from the Colorado Cancer Registry and assessed for recurrence rates as well as median local disease-free and overall survival.
  • Although the number of cases in this report is small, it represents the largest total and longest follow-up for tubular breast cancer cases after excision alone.
  • This report suggests that breast irradiation could be omitted after conservative surgery in older patients with smaller (< or =3 cm) tubular/well-differentiated breast cancers.
  • [MeSH-major] Adenocarcinoma / surgery. Breast Neoplasms / surgery. Mastectomy, Segmental

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730459.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Fernández-Aguilar S, Simon P, Buxant F, Simonart T, Noël JC: Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas. Virchows Arch; 2005 Oct;447(4):683-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas.
  • We have examined 23 cases of pure tubular carcinomas (TCs) of the breast and 53 cases of invasive ductal low-grade carcinomas to determine the relationship and distribution of intra-epithelial lesions, mainly of ductal in situ carcinoma type, but including also lobular intra-epithelial neoplasia (LIN) in both entities.
  • Eleven cases of TC showed flat epithelial atypia (FEA) (47.8%), and, in 14 and 6 cases, micropapillary and cribriform low-grade ductal carcinoma in situ (DCIS) were present (60.7 and 26.1%, respectively).
  • On the opposite, in ductal grade I invasive carcinomas, the most frequent architectural pattern was low-grade DCIS growing in arcades in 26 cases (49%).
  • While absent in TCs, low-grade DCIS of solid type was found in five (9.4%) cases of ductal invasive carcinomas, where FEA were present in seven (13.2%) cases.
  • LIN lesions were present in four (17.4%) cases of TC, whereas they represented 7.5%, as reported by Carstens et al. (Am J Clin Pathol 58:231-238, 1972), of cases of low-grade carcinomas.
  • These results suggest that invasive pure TC and low-grade ductal carcinomas of the breast are different lesions, and support the fact that TC, of low histopathological grade, is a particular distinct tumoural entity.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091953.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Itatsu K, Sano T, Hiraoka N, Ojima H, Takahashi Y, Sakamoto Y, Shimada K, Kosuge T: Intraductal tubular carcinoma in an adenoma of the main pancreatic duct of the pancreas head. J Gastroenterol; 2006 Jul;41(7):702-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular carcinoma in an adenoma of the main pancreatic duct of the pancreas head.
  • Microscopically, the tumor was an intraductal tubular carcinoma (ITC) in a tubular adenoma, suggesting direct histologic evidence of the adenoma-carcinoma sequence in intraductal tubular tumors, differing from previous reports of ITCs describing de novo-like development.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933009.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Noriyuki T, Okumichi T, Kimura A, Koga R, Takeshima Y: [Mucoepidermoid carcinoma with high level of serous carcinoembryonic antigen; report of a case]. Kyobu Geka; 2005 Jul;58(7):592-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucoepidermoid carcinoma with high level of serous carcinoembryonic antigen; report of a case].
  • We reported a case of mucoepidermoid carcinoma with a high level of the serum CEA.
  • Bronchoscopic biopsy suggested a diagnosis of tubular adenocarcinoma.
  • Histopathologically, the polypoid tumor was a low grade mucoepidermoid carcinoma with partially extrabronchial extension.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / blood. Carcinoma, Mucoepidermoid / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004345.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


34. Leikola J, Heikkilä P, von Smitten K, Leidenius M: The prevalence of axillary lymph-node metastases in patients with pure tubular carcinoma of the breast and sentinel node biopsy. Eur J Surg Oncol; 2006 Jun;32(5):488-91
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of axillary lymph-node metastases in patients with pure tubular carcinoma of the breast and sentinel node biopsy.
  • AIMS: We aimed to evaluate the prevalence of and the risk factors for axillary lymph-node metastases in pure tubular carcinoma (PTC) of the breast.
  • To confirm the correct histological diagnosis (PTC, >90% tubular component), the breast tumours were reviewed by an expert breast pathologist.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569494.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


35. Galvão FH, Pestana JO, Capelozzi VL: Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol; 2010 Feb;65(3):607-10
MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
  • In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma.
  • A 72-year-old patient was submitted to an elective laparoscopic cholecystectomy, and a tubular adenocarcinoma in the gallbladder was incidentally diagnosed.
  • The colonic lesion was conveniently removed and the histology evaluation confirmed the diagnosis of adenocarcinoma tubular.
  • [MeSH-major] Adenocarcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Lung Diseases, Interstitial / chemically induced

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2002;20(7-8):876-9 [12449717.001]
  • [Cites] J Thorac Oncol. 2009 Jul;4(7):845-52 [19487963.001]
  • [Cites] Br J Dermatol. 1997 Feb;136(2):279-82 [9068751.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):286-91 [9217042.001]
  • [Cites] Cancer. 2006 May 1;106(9):2051-7 [16568459.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1759-60 [16685265.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):434-40 [17409896.001]
  • [Cites] Anticancer Drugs. 2007 Oct;18(9):1109-11 [17704662.001]
  • [Cites] Invest New Drugs. 2008 Feb;26(1):67-74 [17805486.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Jan;35(1):133-6 [18195543.001]
  • [Cites] Chest. 2008 Feb;133(2):528-38 [18252919.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(2):179-81 [18459559.001]
  • [Cites] Oncologist. 2008 Jul;13(7):807-11 [18614588.001]
  • [Cites] Hum Pathol. 2008 Sep;39(9):1275-94 [18706349.001]
  • [Cites] JOP. 2008;9(6):708-14 [18981552.001]
  • [Cites] Arch Gynecol Obstet. 2009 Feb;279(2):251-4 [18548263.001]
  • [Cites] Eur J Med Res. 2009;14:90-2 [19258219.001]
  • [Cites] Clin Pharmacol Ther. 1981 Aug;30(2):239-45 [7249508.001]
  • (PMID = 19904536.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


36. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK: Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg; 2007 Oct;194(4):527-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy.
  • BACKGROUND: Mucinous, medullary, and tubular carcinomas are uncommon types of breast cancer whose rarity does not permit large single-institution studies or randomized trials to define optimal treatments.
  • In this study, we evaluated the long-term outcomes of breast-conserving therapy (BCT) for these subtypes of breast cancer and compared them with those for invasive ductal carcinoma.
  • METHODS: In our institutional database of patients who received BCT from 1965 to 1999, 1,643 patients with stage I to II mucinous (61), medullary (37), tubular (60), and invasive ductal (1,485) histologies were identified.
  • Only patients with tubular carcinoma had better 5- and 10-year OS rates (P = .013).
  • In multivariable analysis, factors associated with improved OS included age at or below 50 years, negative nodal status, use of chemotherapy or hormonal therapy, and tubular histology.
  • CONCLUSIONS: BCT for mucinous, medullary, or tubular carcinoma resulted in similar local-regional failure rates to that for invasive ductal carcinoma.
  • Tubular carcinoma patients had the most favorable OS.
  • BCT is an appropriate treatment strategy for early-stage mucinous, medullary, and tubular carcinomas.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / surgery. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826073.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Tanaka H, Takamori H, Eto S, Ozaki N, Akaboshi S, Nakahara O, Ida S, Furuhashi S, Abe S, Horino K, Beppu T, Baba H: [Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1783-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological diagnosis was tubular adenocarcinoma of the pancreas.


38. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol; 2007 Mar;31(3):417-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
  • This study was undertaken to determine the morphologic features and frequency of putative precursor lesions involved in the development of some pure forms of special types and low grade breast carcinoma.
  • We reviewed 147 successive tumor cases, comprising tubular carcinoma (TC); pure type (n=56) and mixed type (n=20), invasive lobular carcinoma (ILC); classic type (n=57), and tubulolobular carcinoma (TLC; n=14).
  • The presence of preinvasive lesions including columnar cell lesions (CCLs), usual epithelial hyperplasia, ductal carcinoma in situ (DCIS), and lobular neoplasia (LN) was determined.
  • Molecular studies are being performed to substantiate the hypothesis that tubular and lobular carcinomas have direct evolutionary links to CCLs and flat epithelial atypia.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Epithelial Cells / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):7-21 [23959112.001]
  • (PMID = 17325484.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Receptors, Estrogen
  •  go-up   go-down


39. Brandt SM, Young GQ, Hoda SA: The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol; 2008 May;15(3):140-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions.
  • The histologic triad of tubular carcinoma (TC), columnar cell lesion (CCL), and lobular carcinoma in situ (LCIS) has been recognized, but has not yet been fully characterized.
  • The "Rosen Triad"-named in tribute to its first categorical description by the eponymous pathologist-is a morphologic observation that may have important clinical and pathologic implications.
  • The diagnosis of TC was confirmed in 86 of our cases, and relevant patient data were analyzed.
  • Although cases of TC that were associated with LCIS (vs. those not associated with LCIS) seemed to be slightly more likely to have multifocal TC, have another synchronous higher-grade invasive carcinoma and show nodal positivity, these differences were not found to be statistically significant (P<0.05).
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Hyperplasia. Mammary Glands, Human / pathology. Middle Aged. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434766.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


40. Esposito NN, Chivukula M, Dabbs DJ: The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol; 2007 Jan;20(1):130-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study.
  • Tubulolobular carcinoma is a type of mammary carcinoma that displays an admixture of invasive tubules and lobular-like cells.
  • Previous reports have shown it to share clinical similarities to lobular carcinoma, whereas more recent studies have shown it to be E-cadherin positive.
  • The aim of the current study was to further explore the immunophenotype of tubulolobular carcinoma, and to document its natural behavior.
  • Nineteen cases of tubulolobular carcinoma and 10 cases each of tubular and lobular carcinoma were retrieved for comparison analysis.
  • Twenty-five percent of patients with tubulolobular carcinoma presented with greater than stage I disease, compared to 0 and 60% of patients with tubular and lobular carcinoma, respectively.
  • Two patients with tubulolobular carcinoma had tumor recurrence, one of whom also developed metastasis.
  • The majority of all carcinomas were estrogen and progesterone receptor positive.
  • E-cadherin displayed membranous staining in all tubular and tubulolobular carcinomas, and was negative in all lobular carcinomas.
  • Half of each carcinoma subtype displayed granular cytoplasmic 34betaE12 immunoreactivity. alpha-Catenin exhibited partial or complete membranous staining in all tubulolobular and tubular carcinomas, and was negative in all lobular carcinomas. beta-Catenin displayed membranous staining in tubulolobular and tubular carcinomas, whereas all lobular carcinomas had coarse cytoplasmic immunoreactivity. p120 and gamma-catenin displayed membranous staining in 100% of tubulolobular and tubular carcinomas and cytoplasmic staining in 100% of lobular carcinomas.
  • Tubulolobular carcinoma of the breast is thus a distinct type of mammary carcinoma that displays both tubular and lobular patterns histologically but displays the membranous E-cadherin/catenin complex characteristic of the ductal immunophenotype.
  • Tubulolobular carcinoma appears to be more aggressive than tubular carcinoma, as 16% of patients had lymph node metastases, although all were alive at a mean follow-up of 40 months.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Cadherins / analysis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Catenins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Lymph Nodes / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Prognosis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mod Pathol. 2008 Aug;21(8):1058; author reply 1058-9 [18654593.001]
  • (PMID = 17143261.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Cadherins; 0 / Catenins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


41. Satoh Y, Hoshi R, Tsuzuku M, Ishikawa Y, Inamura K, Horai T: Cytology of pulmonary adenocarcinomas showing enteric differentiation. Acta Cytol; 2006 May-Jun;50(3):250-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of pulmonary adenocarcinomas showing enteric differentiation.
  • OBJECTIVE: To evaluate cytologic differences between primary pulmonary adenocarcinomas showing enteric differentiation (PAED) primary pulmonary adenocarcinomas of ordinary structure (PAC) and pulmonary metastases from colorectal carcinomas (MCR).
  • Aspiration cytologic and/or imprint smears of routine samples stained by the Papanicolaou method from the PAED cases were reviewed in comparison with 10 cases each of PAC showing a tubular pattern and MCR.
  • CONCLUSION: Although diagnosis of PAED by routine cytology is difficult due to the features of the lesion, differential diagnosis between PAED, PAC and MCR is a possible using conventional cytologic criteria.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Lung / pathology. Lung Neoplasms / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Needle. Cell Differentiation. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780017.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, Yamamoto M, Kawamura S, Kobayashi M, Ishida K, Morikawa T, Motoi F, Unno M, Kanno A, Satoh K, Shimosegawa T, Orikasa H, Watanabe T, Nishimura K, Ebihara Y, Koike N, Furukawa T: Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol; 2009 Aug;33(8):1164-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the features of ITPN were distinct from those of other known intraductal pancreatic neoplasms, including pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and the intraductal variant of acinar cell carcinoma.
  • Intraductal tubular carcinomas showed several features that were similar to those of ITPN, except for the tubulopapillary growth pattern.
  • In conclusion, ITPNs can be considered to represent a new disease entity encompassing intraductal tubular carcinoma as a morphologic variant.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440145.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Fukushima N, Mukai K: [Pathologic characteristics and evaluation of the pancreatic cancer]. Gan To Kagaku Ryoho; 2005 May;32(5):599-604
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ductal adenocarcinoma is the most common tumor type of cancer of the pancreas.
  • Histologically, it is often well-to moderately-differentiated tubular adenocarcinoma along with marked desmoplastic change.
  • PanIN is now considered to be a precursor of pancreatic ductal adenocarcinoma based on molecular studies.
  • IPMNs and MCNs can form similar invasive carcinomas such as tubular adenocarcinoma and/or mucinous carcinoma.
  • Careful attention should be paid to the processes and/or criteria of pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / pathology. DNA-Binding Proteins / genetics. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Smad4 Protein. Trans-Activators / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918557.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators
  •  go-up   go-down


44. Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum; 2006 May;49(5):588-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
  • PURPOSE: The aim of this study was to investigate the immunohistochemical expression of p16, p53, and p63 proteins according to some pathologic parameters related to colorectal adenomas and adenocarcinomas such as grade of dysplasia and histologic type.
  • METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30).
  • RESULTS: The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
  • P63 expression was found mainly in the villous adenomas and in the poorly differentiated adenocarcinomas.
  • The poorly differentiated adenocarcinomas also exhibited coexpression of CK5 and p63.
  • However, p63 expression was closely associated with villous adenomas and poorly differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma. Adenoma. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575619.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


45. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T: Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. Am J Surg Pathol; 2007 Apr;31(4):569-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas.
  • BACKGROUND: Adenocarcinoma of the distal esophagus and gastric cardia are defined by the relationship of its epicenter to the gastro-esophageal junction, which is presently defined as the end of the tubular esophagus.
  • AIM: To reclassify adenocarcinomas of this region by the relationship of the tumor to the proximal limit of gastric oxyntic mucosa.
  • METHODS: Seventy-four patients who had esophago-gastrectomy for adenocarcinomas in this region were classified as adenocarcinoma of distal esophagus (38 patients) and gastric cardia (36 patients) by present criteria.
  • CONCLUSIONS: If the gastro-esophageal junction is defined histologically as the proximal limit of oxyntic mucosa, 71/74 patients would be classified as adenocarcinoma of the distal esophagus.
  • We suggest that this reclassification based on the proposed new definition of the gastro-esophageal junction provides an explanation for the epidemiologic relationship that exists between adenocarcinoma of the "gastric cardia" and gastro-esophageal reflux disease.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Esophageal Neoplasms / classification. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414104.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Korinth D, Pacyna-Gengelbach M, Deutschmann N, Hattenberger S, Bockmühl U, Dietel M, Schroeder HG, Donhuijsen K, Petersen I: Chromosomal imbalances in wood dust-related adenocarcinomas of the inner nose and their associations with pathological parameters. J Pathol; 2005 Oct;207(2):207-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in wood dust-related adenocarcinomas of the inner nose and their associations with pathological parameters.
  • Comparative genomic hybridization (CGH) was used to screen 42 wood dust-related sinonasal adenocarcinomas for chromosomal alterations.
  • The tumour collection comprised 39 papillary-tubular cylinder cell adenocarcinomas (PTCCs; six cases G1, 23 G2, and ten G3), two alveolar goblet cell adenocarcinomas (AGCs), and one signet ring cell adenocarcinoma (SRC), according to the Kleinsasser and Schroeder classification.
  • The one carcinoma without imbalances was a PTCC-G1.
  • These data provide further evidence for a recurrent pattern of chromosomal imbalances in sinonasal adenocarcinomas and highlight distinct aberrations that are associated with tumour differentiation and progression.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Occupational Diseases / genetics. Paranasal Sinus Neoplasms / genetics. Wood
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / etiology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / etiology. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / pathology. Cell Differentiation / physiology. DNA, Neoplasm / genetics. Dust. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16041693.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Dust
  •  go-up   go-down


47. Honda T, Tamura G, Endoh Y, Nishizuka S, Kawata S, Motoyama T: Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach. Jpn J Clin Oncol; 2005 Oct;35(10):580-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach.
  • We attempted to clarify the derivation of undifferentiated-type gastric carcinoma with tubular component by using TMA.
  • METHODS: We constructed a TMA system composed of six paraffin blocks in which 274 samples of formalin-fixed gastric carcinoma tissue from 274 patients were embedded.
  • The 274 gastric carcinomas were histopathologically divided into the following three groups according to the degree of differentiation: differentiated-type (D-type), undifferentiated-type with tubular component (UT-type) and pure undifferentiated-type (UP-type).
  • RESULTS: The percentages of abnormal expression of each protein in D-type, UT-type and UP-type carcinomas were as follows: 27% (38/143), 17% (17/98) and 15% (5/33) for p53; 27% (39/143), 19% (19/98) and 18% (6/33) for p16; 38% (54/143), 44% (43/98) and 24% (8/33) for hMLH1; 15% (22/143), 5% (5/98) and 0% (0/33) for c-erbB-2; and 22% (31/143), 35% (34/98) and 70% (23/33) for CEA.
  • UP-type carcinomas exhibited the lowest frequencies of abnormal expression for p53, p16, hMLH1 and c-erbB-2, but the highest frequencies for CEA.
  • UT-type carcinomas generally showed intermediate frequencies between those of D-type and UP-type carcinomas.
  • CONCLUSIONS: These findings reveal that gastric carcinomas have distinct expression profiles for tumor suppressor and tumor-related proteins depending on histological types, and support the hypothesis that UT-type carcinomas are derived not only from D-type but also from UP-type carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma / genetics. Carrier Proteins / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Nuclear Proteins / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254038.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carcinoembryonic Antigen; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


48. Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP: [Clonal association of flat epithelial atypia and tubular breast cancer]. Pathologe; 2008 Nov;29 Suppl 2:353-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clonal association of flat epithelial atypia and tubular breast cancer].
  • Especially tubular carcinomas, with which FEA shares cytological features, often occur in close proximity to each other.
  • To examine a possible clonal relationship, we analysed mutations of the highly variable region of the mitochondrial genome in a series of tubular carcinomas, associated FEA and normal glands.
  • Our data indicate a possible precursor role of FEA in the development of tubular breast cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. DNA, Mitochondrial / genetics. Epithelial Cells / pathology. Precancerous Conditions / genetics
  • [MeSH-minor] Aged. Breast / pathology. Calcinosis / genetics. Calcinosis / pathology. Cell Nucleus / genetics. Cell Nucleus / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712391.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


49. Wijetunge S, Ma Y, DeMeester S, Hagen J, DeMeester T, Chandrasoma P: Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology. Am J Surg Pathol; 2010 Oct;34(10):1521-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology.
  • Controversy exists as to whether adenocarcinomas occurring in the gastroesophageal junctional region and gastric cardia originate in the esophagus or the stomach.
  • Esophageal adenocarcinoma is known to be strongly associated with gastroesophageal reflux disease; gastric adenocarcinoma with Helicobacter pylori gastritis, and gastric intestinal metaplasia.
  • Between 2004 and 2008, 234 patients were diagnosed with high-grade dysplasia (HGD) and/or adenocarcinoma; 107 were distal esophageal, 79 straddled the distal end of the tubular esophagus, and 48 were in the "gastric cardia."
  • There was no gastritis, H. pylori infection, or intestinal metaplasia in 88/107 (82.2%) of the patients with distal esophageal HGD and/or adenocarcinoma, 70/79 (88.6%) with junctional HGD and/or adenocarcinoma, and 43/48 (85.9%) with "gastric cardiac" HGD and/or adenocarcinoma.
  • The incidence of gastritis was significantly higher in the patients with HGD and/or adenocarcinoma (33/234 or 14.1%) than in the control population (146/2146 or 9.0%; P=0.01).
  • This difference was largely the result of a higher incidence of gastritis in patients with HGD and/or adenocarcinoma in the distal third of the esophagus (19/107 or 17.8%) versus the control population (146/2146 or 9.0%; P=0.01).
  • The incidence of H. pylori positivity was also significantly higher in the patients with HGD and/or adenocarcinoma in the distal third of the esophagus (13/107 or 12.2%) than in the control population (117/2146 or 5.5%; P=0.01).
  • There was no significant difference between the control group and the patients with junctional and gastric cardiac HGD and/or adenocarcinoma for gastritis, H. pylori infection, or the gastric intestinal metaplasia.
  • The absence of gastritis, H. pylori, and the gastric intestinal metaplasia in 85.9% of the patients with HGD and/or adenocarcinoma of the gastroesophageal junctional region strongly suggest that most of these originate in the esophagus.
  • In the small minority of patients whose HGD and/or adenocarcinoma were associated with gastric pathology, the incidence of gastritis and H. pylori infection was significantly higher in patients with HGD and/or adenocarcinoma in the distal third of the esophagus and not in the junctional and "gastric cardiac" tumors.
  • This suggests that the reflux of the gastric juice whose composition has been altered by gastritis and H. pylori infection may be associated with an increased tendency to HGD and/or adenocarcinoma in the distal third of the esophagus.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophagogastric Junction / pathology. Stomach / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871225.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, Jan YY, Huang SF, Nimura Y, Nakanuma Y: Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol; 2006 Feb;44(2):350-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-seven cases of ICC in hepatolithiasis were divided into 18 tubular adenocarcinomas with BilIN, 10 tubular adenocarcinomas with IPN-B and nine colloid carcinomas with IPN-B.
  • IPN-B was characterized by the intestinal phenotype (MUC2+/CK20+), and carcinogenesis leading to tubular adenocarcinoma was associated with increasing MUC1 expression and that to colloid carcinoma with MUC1-negativity.
  • Pathological stages of tubular adenocarcinoma of ICC with BilIN or IPN-B were more advanced than those of colloid carcinoma with IPN-B.
  • Increased expression of MUC1 in BilIN and also IPN-B is associated with tubular adenocarcinoma, while colloid carcinoma in IPN-B is characterized by MUC1-negativity and less advanced pathologic stages.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Cholelithiasis / pathology. Keratins / biosynthesis. Mucins / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Diagnosis, Differential. Disease Progression. Humans. Immunohistochemistry. Neoplasm Staging. Precancerous Conditions

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallstones.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • (PMID = 16360234.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


51. Ho BC, Tan PH: Flat epithelial atypia: concepts and controversies of an intraductal lesion of the breast. Pathology; 2005 Apr;37(2):105-11
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from cancer, on these biopsies we are increasingly recognising a hitherto poorly categorised group of benign to atypical entities collectively known as columnar cell lesions.
  • There is emerging evidence to suggest that flat epithelial atypia may represent a precursor of or the earliest morphologically recognisable form of low-grade ductal carcinoma in situ.
  • In addition, these lesions are often associated with tubular carcinomas and lobular neoplasia.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Epithelial Cells / pathology. Precancerous Conditions / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028837.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


52. Hwangbo S, Kim J, Kim H, Kim J, Kang C, Lee H: Two separated ileal adenocarcinomas in neurofibromatosis type 1. Yonsei Med J; 2007 Dec 31;48(6):1039-42
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two separated ileal adenocarcinomas in neurofibromatosis type 1.
  • Here, we document a rare case of two separated ileal adenocarcinomas in NF-1.
  • The adenocarcinomas were surrounded by a diffuse tubular adenomatous lesion of the mucosa, and ganglion cells were scattered in the NF background.
  • We found this case meaningful for several reasons: two separated adenocarcinomas arising in an unusual ileal segment, the association with precancerous tubular adenoma, and the presence of ganglion cells, which suggests ganglioneuromatosis in NF-1.
  • [MeSH-major] Adenocarcinoma / pathology. Ileal Neoplasms / pathology. Neurofibromatosis 1 / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Feb;27(2):219-24 [12658132.001]
  • [Cites] Yonsei Med J. 2004 Jun 30;45(3):564-7 [15227750.001]
  • [Cites] Neurology. 1974 Dec;24(12):1144-51 [4374669.001]
  • [Cites] Am J Clin Pathol. 1981 Feb;75(2):225-9 [7468527.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):250-7 [7906923.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(1):105-9 [6792771.001]
  • [Cites] Am J Gastroenterol. 1982 Mar;77(3):149-51 [6805310.001]
  • [Cites] Gut. 1987 Sep;28(9):1173-6 [3119436.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):702-15 [2167140.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • (PMID = 18159599.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628198
  • [Keywords] NOTNLM ; Neurofibromatosis / adenocarcinoma / ileum
  •  go-up   go-down


53. Caruso RA, Basile G, Crisafulli C, Pizzi G, Finocchiaro G, Fedele F, Paparo D, Parisi A: Granulomatous inflammatory reaction in human gastric adenocarcinomas: a light and electron microscopy study. Ultrastruct Pathol; 2009 Dec;33(6):269-73
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous inflammatory reaction in human gastric adenocarcinomas: a light and electron microscopy study.
  • The authors report 9 cases of papillary-tubular gastric adenocarcinomas characterized by mature granulomas associated with recent microhemorrhages.
  • This study provides morphological examples of skewed type II macrophage infiltration in gastric adenocarcinomas that is involved in scavenging activity, particularly erythrophagocytosis, formation of mature (nonepithelioid granulomas), and heterotypic aggregation with eosinophils.
  • [MeSH-major] Adenocarcinoma / pathology. Granuloma / pathology. Macrophages / immunology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929174.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD68 antigen, human
  •  go-up   go-down


54. Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S: Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch; 2008 Jun;452(6):589-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?
  • Columnar cell lesions (CCLs) are one of the most common abnormalities in the adult female human breast, characterized by the presence of columnar-shaped epithelial cells lining enlarged terminal-duct lobular units.
  • Columnar cell-like lesions have been described under a variety of names such as blunt duct adenosis, flat epithelial atypia, and ductal intraepithelial neoplasia type DIN1a.
  • The current histologic classification used by some pathologists divides them into simple columnar cell change and columnar cell hyperplasia, both of which can occur with or without atypia.
  • The cellular origin of CCLs and their possible relationship to either expansion or metaplasia of a preexisting normal cell phenotype remains unclear.
  • CCLs are frequently associated with lobular and ductal in situ tumors and invasive lobular and tubular carcinomas.
  • The relationship and natural history of CCLs to invasive ductal carcinoma is enigmatic, but they may prove of clinical relevance when detected by screening mammography.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Estrogen Receptor alpha / analysis. Female. Humans. Immunohistochemistry. Mammography. Receptors, Androgen / analysis. Receptors, Progesterone / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437416.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Receptors, Androgen; 0 / Receptors, Progesterone
  • [Number-of-references] 79
  •  go-up   go-down


55. Jo VY, Mills SE, Cathro HP, Carlson DL, Stelow EB: Low-grade sinonasal adenocarcinomas: the association with and distinction from respiratory epithelial adenomatoid hamartomas and other glandular lesions. Am J Surg Pathol; 2009 Mar;33(3):401-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade sinonasal adenocarcinomas: the association with and distinction from respiratory epithelial adenomatoid hamartomas and other glandular lesions.
  • Sinonasal adenocarcinomas (SNACs) are uncommon malignancies that show a variety of growth patterns.
  • Nine (31%) low-grade SNACs demonstrated a predominantly exophytic and papillary growth pattern, and 18 (72%) had a more tubular growth pattern.
  • Six low-grade tubular SNACs were associated with REAHs.
  • This association of low-grade tubular SNACs with REAHs suggests that REAHs may be related to some adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Hamartoma / pathology. Nose Neoplasms / pathology. Paranasal Sinuses / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011560.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Mozzachio AM, Rusiecki JA, Hoppin JA, Mahajan R, Patel R, Beane-Freeman L, Alavanja MC: Chlorothalonil exposure and cancer incidence among pesticide applicator participants in the agricultural health study. Environ Res; 2008 Nov;108(3):400-3
Hazardous Substances Data Bank. CHLOROTHALONIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rodent studies have shown evidence of renal tubular carcinomas and adenomas.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:366-77 [17119216.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Regul Toxicol Pharmacol. 1996 Aug;24(1 Pt 1):69-84 [8921547.001]
  • [Cites] Cancer Invest. 2005;23(8):700-11 [16377589.001]
  • [Cites] Scand J Work Environ Health. 1992 Aug;18(4):209-15 [1411362.001]
  • (PMID = 18801479.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010119-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fungicides, Industrial; 0 / Nitriles; J718M71A7A / tetrachloroisophthalonitrile
  • [Other-IDs] NLM/ NIHMS232304; NLM/ PMC2936501
  •  go-up   go-down


57. Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA: Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther; 2005 Mar;4(3):302-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.
  • Using nonradioactive in situ hybridization, we evaluated the gene expression patterns of three genes previously shown to be robust markers of the juxtatumoral stroma within eight infiltrating ductal adenocarcinoma of the pancreas (ApoC1, ApoD and MMP11), and compared these patterns to those associated with seven infiltrating colloid and tubular carcinomas arising in association with intraductal papillary mucinous neoplasms (IPMNs), a histologically distinct form of primary carcinoma of the pancreas, two surgically resected samples of chronic pancreatitis and two surgically resected pancreatic cancer liver metastases.
  • Robust juxtatumoral stromal expression was noted for all three markers within all eight conventional infiltrating ductal adenocarcinoma tissues, but not in samples of chronic pancreatitis.
  • Among the carcinomas arising within an IPMN, expression for all three markers was also noted for five of seven infiltrating carcinomas analyzed.
  • However, when labeling for these three markers was analyzed with respect to infiltrative growth pattern, positive labeling was only seen in areas of tubular (ductal-type) growth and not in areas of colloid carcinoma.
  • This observation was further supported by two infiltrating carcinomas arising in an IPMN that showed both tubular and colloid growth patterns within the same neoplasm indicating the host stromal response observed may relate to infiltrative growth pattern rather than the biology of the primary tumor type.
  • Moreover, these robust patterns within conventional infiltrating ductal adenocarcinomas were not retained within matched metastases to the liver, indicating the importance of the tumor microenvironment in the host stromal response.
  • Juxtatumoral stroma was found to be composed of a least two cell types, tumor-infiltrating macrophages and fibroblasts, highlighting the complexity of tumor-stromal interactions within an infiltrating carcinoma.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma / genetics. Carcinoma / secondary. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Apolipoprotein C-I. Apolipoproteins / analysis. Apolipoproteins / genetics. Apolipoproteins C / analysis. Apolipoproteins C / genetics. Apolipoproteins D. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / secondary. Cell Communication / genetics. Gene Expression. Glycoproteins / analysis. Glycoproteins / genetics. Humans. In Situ Hybridization. Liver Neoplasms / chemistry. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Matrix Metalloproteinase 11. Membrane Transport Proteins / analysis. Membrane Transport Proteins / genetics. Metalloendopeptidases / analysis. Metalloendopeptidases / genetics. RNA, Messenger / analysis. RNA, Messenger / metabolism. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876873.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA1066110; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / Apolipoprotein C-I; 0 / Apolipoproteins; 0 / Apolipoproteins C; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


58. de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, Vincent-Salomon A, Soubeyran I, Picot V, Coindre JM, Mauriac L: Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-up. Virchows Arch; 2007 Jul;451(1):1-10
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study analyzes the occurrence of epithelial atypia in 2,833 serially sectioned surgical breast biopsies (SB) performed for microcalcifications (median number of blocks per SB:26) and the occurrence of subsequent cancer after an initial diagnosis of epithelial atypia (median follow-up 160 months).
  • Concomitant cancers corresponded to ductal carcinomas in situ and micro-invasive (77%), invasive ductal carcinomas not otherwise specified (15%), invasive lobular carcinomas (4%), and tubular carcinomas (4%).
  • The high slide rating might explain the high percentages of epithelial atypia and concomitant cancers and the low percentage of subsequent cancer after a diagnosis of epithelial atypia as a single lesion.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Epithelium / pathology. Female. Follow-Up Studies. Humans. Hyperplasia. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1991 Dec;22(12):1232-9 [1748429.001]
  • [Cites] Int J Cancer. 1991 Mar 12;47(5):703-6 [2004851.001]
  • [Cites] Pathol Annu. 1993;28 Pt 1:1-13 [8416134.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1258-65 [8435803.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3896-907 [8389654.001]
  • [Cites] Radiology. 1993 Dec;189(3):667-71 [8234688.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):223-35 [7831534.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1310-9 [7882281.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):2-13 [7770672.001]
  • [Cites] Ann Pathol. 1996 Nov;16(5):315-33 [9004719.001]
  • [Cites] Am J Clin Pathol. 1997 May;107(5):561-6 [9128269.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1798-802 [9351550.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):140-54 [9504685.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1521-7 [9850178.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):291-9 [10430122.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):413-21 [10526005.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):534-43 [15767810.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1227-33 [16894523.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2698-708 [2986821.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1561 [10584711.001]
  • [Cites] Cancer. 2000 May 1;88(9):2072-81 [10813719.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):700-3 [10843367.001]
  • [Cites] Breast Cancer Res Treat. 2000 May;61(2):151-9 [10942101.001]
  • [Cites] Radiology. 2000 Sep;216(3):831-7 [10966718.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Breast Cancer. 2000;7(4):326-31 [11114859.001]
  • [Cites] Radiology. 2001 Feb;218(2):503-9 [11161169.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1017-21 [11474285.001]
  • [Cites] Int J Surg Pathol. 2001 Jul;9(3):201-6 [11584316.001]
  • [Cites] Breast J. 2002 Mar-Apr;8(2):70-6 [11896750.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):421-30 [11914619.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):697-701 [12033958.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):797-9 [12090431.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1095-110 [12218567.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):120-9 [12591964.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):325-33 [12604888.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Semin Diagn Pathol. 2004 Feb;21(1):10-7 [15074554.001]
  • [Cites] Semin Diagn Pathol. 2004 Feb;21(1):18-24 [15074555.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):242-50 [15241819.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):996-9 [15335264.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Cancer. 1978 Aug;42(2):737-69 [209887.001]
  • [Cites] Am J Surg Pathol. 1978 Sep;2(3):225-51 [210682.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):179-81 [3965938.001]
  • [Cites] Am J Epidemiol. 1987 May;125(5):769-79 [3565352.001]
  • [Cites] Cancer. 1988 May 15;61(10):2077-82 [3359405.001]
  • [Cites] Am J Epidemiol. 1988 Sep;128(3):467-77 [3414655.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):518-29 [2297643.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):578-83 [2337206.001]
  • [Cites] Hum Pathol. 1992 Oct;23(10):1095-7 [1328030.001]
  • (PMID = 17551752.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2335297
  •  go-up   go-down


59. Altorjay A, Paal B, Sohar N, Kiss J, Szanto I, Sohar I: Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus. World J Gastroenterol; 2005 Oct 7;11(37):5751-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus.
  • AIM: To establish whether there are fundamental differences in the biochemistries of adenocarcinomas of the gastroesophageal junction (GEJ) and the squamous cell carcinomas of the lower third of the esophagus (LTE).
  • Of these, 29 were adenocarcinomas of the GEJ Siewert type I (n = 8), type II (n = 12), type III (n = 9), and 18 presented as squamous cell carcinomas of the LTE.
  • These data were further analyzed to establish the correlation with tumor localization, TNM stage (lymph-node involvement), histological type (papillary, signet-ring cell, tubular), state of differentiation (good, moderate, poor), and survival (<or=24 or >or=24 mo).
  • RESULTS: In adenocarcinomas, the activity of alpha-mannosidase (AMAN), cathepsin B (CB) and dipeptidyl-peptidase I (DPP I) increased significantly as compared to the normal gastric mucosa.
  • In squamous cell carcinomas of the esophagus, we also found a significant difference in the activity of cathepsin L and tripeptidyl-peptidase I in addition to these three.
  • There was a statistical correlation of AMAN, CB, and DPP I activity between the level of differentiation of adenocarcinomas of the GEJ and lymph node involvement, because tumors with no lymph node metastases histologically confirmed as well-differentiated, showed a significantly lower activity.
  • CONCLUSION: Adenocarcinomas of the GEJ form a homogenous group from a tumor-biochemical aspect, and differ from the biochemical characteristics of squamous cell carcinomas of the LTE on many points.
  • When adenocarcinomas of the GEJs are examined at the preoperative phase, the ratio of the performed AMAN, CB, and DPP I enzymatic activity of the tissue sample from the tumor and adjacent intact mucosa within 2 cm of the tumor may have a prognostic value even in the preoperative examination period, and may indicate that ranking of these patients into the neo-adjuvant treatment group should be considered.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Squamous Cell. Esophageal Neoplasms. Gastrointestinal Neoplasms. Lysosomes / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270380.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4479671
  •  go-up   go-down


60. Terada T: Intraductal tubular carcinoma, intestinal type, of the pancreas. Pathol Int; 2009 Jan;59(1):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular carcinoma, intestinal type, of the pancreas.
  • Presented herein is an unusual case of intraductal tubular carcinoma, intestinal type, of the pancreas.
  • This tumor was characterized by intraductal adenoma with a few malignant foci, and also by entire involvement of the main pancreatic duct and no involvement of its branches.
  • Because a biopsy showed tubular atypical cells, pancreato-duodenectomy was performed.
  • Microscopically, the entire main pancreatic duct had proliferation of tubular adenomatous tumor without secretory mucins.
  • Malignant transformation was present in a few areas.
  • On mucin histochemistry the tumor cell cytoplasm contained a little or no neutral and acidic mucus, and no secretory mucins were recognized.
  • The tumor cells were negative for p53 protein, but the malignant foci were positive for p53 protein and had high Ki-67 antigen (labeling 60%).
  • In summary, presented here is an extremely rare case of intraductal tubular carcinoma, intestinal type, showing focal malignant foci.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Mucins / metabolism. Pancreatic Neoplasms / pathology


61. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Marchiò C, Sapino A, Arisio R, Bussolati G: A new vision of tubular and tubulo-lobular carcinomas of the breast, as revealed by 3-D modelling. Histopathology; 2006 Apr;48(5):556-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new vision of tubular and tubulo-lobular carcinomas of the breast, as revealed by 3-D modelling.
  • AIMS: To reveal architectural structure and growth patterns of tubular carcinomas (TC) and tubulo-lobular carcinomas (TLC) of the breast.
  • In TLC the structure was similar, but the connecting single-cell files were usually longer.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Imaging, Three-Dimensional / methods. Models, Biological

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623781.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


63. Cserni G: Axillary sentinel lymph node micrometastases with extracapsular extension: a distinct pattern of breast cancer metastasis? J Clin Pathol; 2008 Jan;61(1):115-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumours of the micrometastatic cases with ECE were non-high-grade and often of tubular type.
  • Minimal nodal metastases with ECE may represent a distinct pattern of nodal involvement with a predominant capsular and extracapsular, but only minimal or no nodal parenchymal component, predominantly seen in non-poorly differentiated and/or tubular carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468292.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Karimzadeh M, Sauer T: Diagnostic accuracy of fine-needle aspiration cytology in histological grade 1 breast carcinomas: are we good enough? Cytopathology; 2008 Oct;19(5):279-86
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of fine-needle aspiration cytology in histological grade 1 breast carcinomas: are we good enough?
  • BACKGROUND: Fine-needle aspiration cytology (FNAC) of both palpable and non-palpable breast carcinomas has a high accuracy and sensitivity in dedicated centres.
  • It is generally thought that low-grade carcinomas have a distinctly lower sensitivity due to discrete cellular atypia that may be difficult to appreciate.
  • Grade 1 carcinomas make up about 45% of screening-detected breast carcinomas and about 20% of symptomatic breast cancers.
  • The aim of this study was to evaluate the diagnostic sensitivity of grade 1 carcinomas and identify the critical features in the cytological diagnostic work-up of these tumours.
  • METHODS: There were FNAC smears from 494 histologically confirmed grade 1 carcinomas diagnosed during 1996-2004.
  • RESULTS: A definitive malignant diagnosis (absolute sensitivity) was given in 382 cases (77.3%).
  • Invasive ductal carcinomas comprised 81.3% of all cases; absolute sensitivity for these was 80.9%.
  • Invasive lobular and tubular carcinomas comprised 7.3% and 5.9% of cases, respectively; absolute sensitivity for these diagnosis was 50.0% and 57.1%, respectively, significantly lower than for other subtypes (P <or= 0.0001) whereas the difference for complete sensitivity was less but still significant (P = 0.017).
  • CONCLUSION: Preoperative FNAC diagnosis of grade 1 breast carcinoma has a high sensitivity, especially in ductal carcinomas.
  • Invasive lobular and tubular carcinomas were less likely to receive a definite preoperative diagnosis.
  • The main reason for not reaching a definitive malignant diagnosis was sampling error due to small tumours less than 1 cm in diameter, irrespective of tumour subtype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627406.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Yopp AC, Allen PJ: Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg; 2010 Oct 27;2(10):359-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The five-year survival rates for non-invasive and associated invasive carcinoma are 90% and 40%, respectively in resected IPMN lesions.
  • Invasive carcinoma within IPMN lesions can be further classified by histological subtype into colloid carcinoma and tubular carcinoma.
  • Estimated five-year survival rates following resection of colloid carcinoma range from 57%-83% and estimated five-year survival following resection of tubular carcinoma range from 24%-55%.
  • The difference in survival outcome between invasive colloid and tubular IPMN appears to be a function of disease biology, as patients with the tubular subtype tend to have larger tumors with a propensity for metastasis to regional lymph nodes.
  • When matched to resected conventional pancreatic adenocarcinoma lesions by the Memorial Sloan Kettering Cancer Center pancreatic adenocarcinoma nomogram, the colloid carcinoma histological subtype has an improved estimated five-year survival outcome compared to conventional pancreatic adenocarcinoma, 87% and 23% (P = 0.0001), respectively.
  • Resected lesions with the tubular carcinoma subtype overall have a similar five-year survival outcome compared to conventional pancreatic adenocarcinoma.
  • However, when these groups were stratified by regional lymph node status patients with negative regional lymph nodes and the tubular subtype experienced significantly better survival than patients with a similar nodal status and ductal adenocarcinoma with estimated five-year survival rates of 73% and 27% (P = 0.01), respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160844.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999211
  • [Keywords] NOTNLM ; Intraductal papillary mucinous neoplasms / Pancreatic adenocarcinoma / Prognosis
  •  go-up   go-down


66. Li CI, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Strom BL, Simon MS, Press MF, McDonald JA, Ursin G, Burkman RT, Deapen D, Spirtas R: Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):946-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Important differences in the contributions of certain exposures to the risks of ductal versus lobular breast carcinomas have been observed, but few studies have evaluated the relationships between established breast cancer risk factors and other histologic types.
  • METHODS: Information on family history of cancer and reproductive, hormonal, anthropometric, and lifestyle characteristics were collected in a multicenter population-based case-control study consisting of 3,463 ductal, 274 lobular, 261 ductal-lobular, 91 medullary, 77 tubular, 70 comedo, and 61 mucinous invasive breast carcinoma cases (ages 35-64 years, newly diagnosed 1994-1998) and 4,682 controls.
  • Specifically, current use of unopposed estrogen was associated with a reduced risk of ductal carcinoma and increased risk of comedocarcinoma, and current use of estrogen and progestin was associated with elevated risks of ductal-lobular and tubular carcinomas.
  • Among postmenopausal women, BMI was only inversely related to risk of ductal-lobular carcinoma, and alcohol use was only positively related to risk of lobular carcinoma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / pathology. Adult. Alcohol Drinking / epidemiology. Body Mass Index. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / pathology. Case-Control Studies. Estrogen Replacement Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Regression Analysis. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702375.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / N01-HD-2-3166; United States / NICHD NIH HHS / HD / N01-HD-2-3168; United States / NICHD NIH HHS / HD / N01-HD-3-3174; United States / NICHD NIH HHS / HD / N01-HD-3-3175; United States / NICHD NIH HHS / HD / N01-HD-3-3176; United States / NICHD NIH HHS / HD / Y01-HD-7022
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


67. Riaz N, Khan SM, Idrees R, Kayani N: Infiltrating syringomatous adenoma of nipple. J Coll Physicians Surg Pak; 2008 Jul;18(7):438-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Important differential diagnosis include nipple adenoma, tubular carcinoma and adenosquamous carcinoma.
  • Appropriate local management includes accurate diagnosis and complete excision to avoid local recurrences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760070.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


68. Thirot-Bidault A, Lazure T, Ples R, Dimet S, Dhalluin-Venier V, Fabre M, Pelletier G: [Pancreatic intraductal tubular carcinoma: a sub-group of intraductal papillary-mucinous tumors or a distinct entity? A case report and review of the literature]. Gastroenterol Clin Biol; 2006 Nov;30(11):1301-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic intraductal tubular carcinoma: a sub-group of intraductal papillary-mucinous tumors or a distinct entity? A case report and review of the literature].
  • [Transliterated title] Carcinome tubuleux intracanalaire pancréatique: sous-groupe ou entité distincte des tumeurs intracanalaires papillaires mucineuses? A propos d'un cas et revue de la littérature.
  • The intraductal tumor showed a cribriform pattern, atypical cells without mucus and a MUC1+, MUC2-, MUC5AC- phenotype, all characteristics of intraductal tubular carcinoma, a new entity described by Japanese authors.
  • The differential diagnosis and its relationship with intraductal papillary-mucinous tumors are discussed.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Male. Pancreatectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185972.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 13
  •  go-up   go-down


69. Yoon SN, Roh SA, Cho DH, Kim MB, Hyun YL, Ro S, Kim BS, Kim SY, Kim YS, Kim JC: In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs. Hepatogastroenterology; 2010 May-Jun;57(99-100):657-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
  • Diffuse- or mixed-type carcinomas on Lauren classification were closely associated with increased chemosensitivity to TS-1 (p = 0.044).
  • Node-positive and "other than tubular type" tumors on WHO classification were chemosensitive to cisplatin (p = 0.011 and 0.014, respectively).
  • [MeSH-major] Adenocarcinoma / drug therapy. Histone Deacetylase Inhibitors / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cell Proliferation / drug effects. Female. Humans. In Vitro Techniques. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698245.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors
  •  go-up   go-down


70. Mastropasqua MG, Maiorano E, Pruneri G, Orvieto E, Mazzarol G, Vento AR, Viale G: Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol; 2005 Oct;18(10):1277-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast.
  • Adenoid cystic carcinoma of the breast represents a unique clinicopathologic entity with a variable histological appearance and a relatively indolent clinical course in most of the cases.
  • Adenoid cystic carcinoma may be difficult to differentiate from infiltrating duct carcinomas, and in particular from tubular and cribriform carcinomas, especially in core or vacuum-assisted biopsies.
  • We evaluated the prevalence of c-kit, p63, and e-cadherin immunoreactivity in a series of 20 adenoid cystic carcinomas, comparing the results with those obtained in a series of infiltrating tubular carcinomas and infiltrating cribriform carcinomas.
  • Three (15%) adenoid cystic carcinomas and all infiltrating tubular and cribriform carcinomas showed estrogen receptor and/or progesterone receptor immunoreactivity (P < 0.00001 for estrogen and P = 0.00002 for progesterone receptors).
  • Adenoid cystic carcinomas consistently lacked any immunoreactivity for HER/2, whereas three (15%) infiltrating and cribriform carcinomas showed weak and incomplete membrane staining (P = 0.23077).
  • Membranous immunoreactivity for c-kit was found in all except one (predominantly basaloid) adenoid cystic carcinomas (95%), and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • Nuclear immunoreactivity for p63 was found in all except three (predominantly basaloid) adenoid cystic carcinomas (85%) and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • All infiltrating tubular and cribriform carcinomas and 18/20 (90%) adenoid cystic carcinomas showed immunoreactivity for e-cadherin (P = 0.48718).
  • In summary, adenoid cystic carcinomas showed the following phenotype: estrogen receptor-/progesterone receptor-/c-kit+/p63+ (13 cases, 65%), estrogen receptor-/progesterone receptor/c-kit+/p63- (three cases, 15%), estrogen receptor-/progesterone receptor-/c-kit-/p63+ (one case, 5%), estrogen receptor+/progesterone receptor+/c-kit+/p63+ (two cases, 10%), and estrogen receptor+/progesterone receptor-/c-kit+/p63+ (one case).
  • By contrast, all the infiltrating tubular and cribriform carcinomas showed the estrogen receptor+/progesterone receptor+/c-kit-/p63- phenotype.
  • Our data provide evidence that immunoreactivity for c-kit and/or p63 may be useful in differentiating adenoid cystic carcinomas from other types of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Membrane Proteins / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846389.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cadherins; 0 / Membrane Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


71. Tachihara-Yoshikawa M, Ishida T, Watanabe K, Sugawara A, Kanazawa K, Kanno R, Suzuki T, Niimi T, Kimura S, Munakata M: Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas. Fukushima J Med Sci; 2008 Dec;54(2):61-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas.
  • SCGB3A2 plays a role as an anti-inflammatory agent, however, its role in primary pulmonary carcinomas has not been examined.
  • We assessed immunohistochemical expression of SCGB3A2 in primary pulmonary carcinomas and evaluated the correlation between the expression and histopathological phenotypes and prognosis.
  • SCGB3A2 was predominantly expressed in adenocarcinomas (86.5%), compared with squamous cell carcinomas (50.0%) and small cell carcinomas (42.9%).
  • The expression in papillary adenocarcinomas was seen at higher frequency than that in tubular adenocarcinomas.
  • SCGB3A2 expression in primary pulmonary carcinomas is high, especially in adenocarcinomas.
  • Our results indicate that SCGB3A2 has a potential to be a specific and useful marker for primary pulmonary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Carcinoma, Small Cell / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2006 May 1;173(9):958-64 [16456148.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54358-68 [15485815.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):318-24 [10102618.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:193-201 [11193757.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:234-48 [11193760.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:249-67 [11193761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):2021-36 [11682631.001]
  • [Cites] Am J Hum Genet. 2002 Mar;70(3):718-25 [11813133.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9 [12051626.001]
  • [Cites] Mech Dev. 2002 Jun;114(1-2):201-4 [12175512.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1058-67 [12379752.001]
  • [Cites] Cytogenet Genome Res. 2002;97(1-2):120-7 [12438750.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Dec 1;166(11):1498-509 [12406855.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):924-30 [12847263.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Aug;131(4):291-5 [12915772.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] J Biol Chem. 1995 Mar 24;270(12):6531-6 [7896788.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2056-64 [8628271.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6881-8 [8636114.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):445-52 [8729987.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):30-2 [9059352.001]
  • [Cites] Cell Growth Differ. 1998 Jun;9(6):475-85 [9663466.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):227-31 [10066094.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1193-8 [15531759.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9659-69 [16266985.001]
  • [Cites] Immunol Lett. 2005 Feb 15;97(1):123-9 [15626484.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1673-6 [16980598.001]
  • (PMID = 19418968.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010449-06; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / SCGB3A2 protein, human; 0 / Secretoglobins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9060-09-7 / Uteroglobin
  • [Other-IDs] NLM/ NIHMS102164; NLM/ PMC2743607
  •  go-up   go-down


72. Nakano H, Soda H, Nakamura Y, Uchida K, Takasu M, Nakatomi K, Izumikawa K, Hayashi T, Nagayasu T, Tsukamoto K, Kohno S: Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers. Clin Lung Cancer; 2007 Nov;8(9):562-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the frequency of lung adenocarcinoma has been increasing among nonsmokers, though the etiology remains unclear.
  • Mutations of the epidermal growth factor receptor (EGFR) gene are frequently detected in the lung adenocarcinomas seen in nonsmokers.
  • Thus, EGFR mutations can be implicated in carcinogenesis of lung adenocarcinoma.
  • Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
  • These findings suggest that specific mutations can occur randomly in the EGFR hot spot, and that these EGFR mutations can contribute to the distinct carcinogenic process of each adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Adenocarcinoma, Papillary. Lung Neoplasms. Mutation, Missense. Neoplasms, Multiple Primary / genetics. Receptor, Epidermal Growth Factor / genetics. Sequence Deletion
  • [MeSH-minor] Amino Acid Substitution. Base Sequence. Diagnosis, Differential. Humans. Male. Middle Aged. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186961.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


73. Janke L, Carlson CS, St Hill CA: The novel carbohydrate tumor antigen C2-O-sLe x is upregulated in canine gastric carcinomas. Vet Pathol; 2010 May;47(3):455-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel carbohydrate tumor antigen C2-O-sLe x is upregulated in canine gastric carcinomas.
  • In some canine and human carcinomas, high expression of sLe(x)-decorated carbohydrates has been associated with metastasis and, in humans, a poor prognosis, but detection in canine gastric carcinomas is unreported.
  • The authors hypothesized that these carbohydrates are highly expressed in more malignant types of canine gastric carcinomas, they promote metastasis, and they are associated with a poorer prognosis for dogs.
  • The objectives were to determine the presence and importance of C2-O-sLe(x) expression in canine gastric carcinomas.
  • Routine histological sections of 16 canine gastric carcinomas were categorized on the basis of 3 classification schemes: World Health Organization, Lauren, and Goseki.
  • Signet ring-type carcinomas had markedly higher distribution and intensity of periodic acid-Schiff and alcian blue staining than did tubular carcinomas.
  • These findings suggest that C2-O-sLe(x) is a tumor-associated antigen that may play a role in the invasiveness and metastatic potential of certain types of canine gastric carcinomas.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / metabolism. Carcinoma / veterinary. Dog Diseases / immunology. Oligosaccharides / metabolism. Stomach Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375429.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA111829-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Oligosaccharides
  •  go-up   go-down


74. Shi C, Scudiere JR, Cornish TC, Lam-Himlin D, Park JY, Fox MR, Montgomery EA: Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. Am J Surg Pathol; 2010 Sep;34(9):1344-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile.
  • Clear cell change is seen in <1% of colonic tubular adenomas (TAs) and remains incompletely characterized.
  • Associated adenocarcinomas can also demonstrate a clear cell phenotype.
  • Eleven TAs with at least focal clear cell change with or without associated invasive adenocarcinoma, from 10 patients were studied.
  • Eight of 11 (77%) TAs with clear cell change had focal to extensive high-grade dysplasia.
  • Two were associated with invasive clear cell adenocarcinoma.
  • The adenomas and adenocarcinomas ranged from 0.5 to 3.5 cm.
  • On immunohistochemical studies, the clear cells had decreased MUC2 labeling compared with the surrounding conventional adenoma in 9 of 11 (88%) cases, including the 2 clear cell adenocarcinomas.
  • In 3 of the 11 lesions, the background TA showed at least focal MUC5 immunoreactivity, their associated clear cell area had decreased MUC5 labeling in all 3 cases.
  • Compared with background TA, both increased and decreased expression of CK7, CK20 (in quantity), and CDX2 (in intensity) were observed in the clear cells of TAs and adenocarcinomas.
  • One of the clear cell adenocarcinomas was CK20, CK7, CDX2 and the other was CK20, CK7, CDX2-focal positive.
  • Thus, although the clear cells have different MUC protein profiles than the background adenomatous epithelium, invasive clear cell adenocarcinomas retained the typical CK20(+)/CK7(-) profile of conventional adenocarcinomas.
  • Our results indicate that clear cell adenocarcinomas can be primary to the colorectum with identifiable precursors.
  • Awareness of them and their immunoprofile allows distinction from clear cell lesions from other sites.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Mucins / metabolism. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697252.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


75. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • METHODS: A total of 104 gastric adenocarcinomas from 98 patients (88 infiltrative and 16 intraepithelial tumors) were assessed immunohistochemically for expression of iNOS and occurrence of nitrotyrosine (NTYR)-containing proteins and 8-hydroxy-2'-deoxyguanosine (8-OH-dG)-containing DNA, as markers of NO production and damages to protein and DNA.
  • RESULTS: Tumor cells staining for iNOS, NTYR and 8-OH-dG were detected in 41%, 62% and 50% of infiltrative carcinoma, respectively.
  • The three markers were shown for the first time in intraepithelial carcinoma.
  • The expression of iNOS was significantly more frequent in tubular carcinoma (TC) compared to diffuse carcinoma (DC) (54% vs 18%; P = 0.008) or in polymorphous carcinoma (PolyC) (54% vs 21%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


76. Yu JX, Ren YB, Fu B, Zhao Q, Zhang XD: [Changing trends in the clinicopathological characteristics of patients with gastric carcinoma undergoing surgery between 1979 and 2008 in Liaocheng Shandong province]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Sep;13(9):668-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing trends in the clinicopathological characteristics of patients with gastric carcinoma undergoing surgery between 1979 and 2008 in Liaocheng Shandong province].
  • OBJECTIVE: To evaluate the changing trends in clinicopathological characteristics of patients with gastric carcinoma undergoing surgery between 1979 and 2008.
  • Compared to 1994-1998, there were more poorly differentiated adenocarcinomas during 2004-2008 (62.1% vs. 51.7%, χ2=12.267, P<0.01), and there were less tubular adenocarcinomas during 2004-2008 (23.9% vs. 31.8%, χ2=8.78, P<0.01).
  • In the past 15 years from 1994 to 2008, the proportion of poorly differentiated adenocarcinoma increased, and that of tubular adenocarcinoma declined.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878573.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


77. Ikeda T, Nakayama Y, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Yamashita Y, Kuroki M, Ikeda S: FU-MK-1 expression in human gallbladder carcinoma: an antigenic prediction marker for a better postsurgical prognosis. Am J Clin Pathol; 2009 Jul;132(1):111-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FU-MK-1 expression in human gallbladder carcinoma: an antigenic prediction marker for a better postsurgical prognosis.
  • Gallbladder carcinoma is an aggressive type of neoplasm difficult to cure by conventional procedures.
  • Because of the lack of reliable markers for assessing the prognosis, this retrospective study was designed to investigate the prognostic significance of MK-1 overexpression in human carcinoma of the gallbladder.
  • Immunohistochemical staining using monoclonal antibody FU-MK-1 (MK-1 antigen) was performed on paraffin-embedded tissues from 63 patients who had undergone surgical resection for gallbladder carcinoma.
  • All 21 papillary and 12 of 13 well-differentiated tubular adenocarcinomas but only 1 of 8 poorly differentiated adenocarcinomas were positive for FU-MK-1.
  • These results suggest that MK-1 expression is a prognostic marker in gallbladder carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Antigens, Neoplasm / metabolism. Cell Adhesion Molecules / metabolism. Cholecystectomy. Gallbladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19864241.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  •  go-up   go-down


78. Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol; 2009 May;16(5):1231-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: 117 patients with pancreatic ductal carcinoma, including 89 with invasive tubular adenocarcinoma of the pancreas, Japan Pancreas Society (JPS) stage III-IVb patients, who underwent tumor resection between 1986 and 2006.
  • CONCLUSION: Our results reveal for the first time that it is possible with JPS stage III-IVb invasive tubular adenocarcinomas of the pancreas to differentiate prognostic groups and potential survival rates, like with other cancers.
  • [MeSH-major] Adenocarcinoma / mortality. CA-19-9 Antigen / blood. Carcinoma, Pancreatic Ductal / mortality. Pancreatic Neoplasms / mortality

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263172.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


79. Lerwill MF: Flat epithelial atypia of the breast. Arch Pathol Lab Med; 2008 Apr;132(4):615-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologic, immunohistochemical, and molecular investigations support that flat epithelial atypia represents an early step in the evolution of low-grade ductal carcinomas.
  • It is frequently seen in association with atypical ductal hyperplasia, low-grade ductal carcinoma in situ, invasive tubular carcinoma, and lobular neoplasia.
  • The risk for subsequent breast carcinoma remains to be defined, but flat epithelial atypia likely represents a nonobligate precursor with an extended time course to progression.
  • [MeSH-minor] Biopsy. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384213.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


80. Dang LH, Chen F, Knock SA, Huang EH, Feng J, Appelman HD, Dang DT: CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45. Oncogene; 2006 Mar 30;25(14):2048-59
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45.
  • In mice, ectopic expression of CDX2 in the gastric mucosa gives rise to intestinal metaplasia and in one model, gastric carcinoma.
  • In humans, increased CDX2 expression is associated with gastric intestinal metaplasia and tubular adenocarcinomas.
  • The CDX2 gene in MKN45 gastric carcinoma cells was disrupted using targeted homologous recombination.
  • [MeSH-major] Adenocarcinoma / pathology. Homeodomain Proteins / physiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Cell Cycle. Cell Differentiation. Cell Division. Cell Line, Tumor. DNA Primers. Humans. Immunohistochemistry. Mutation. Recombination, Genetic. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331267.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08DK59970
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / DNA Primers; 0 / Homeodomain Proteins
  •  go-up   go-down


81. Nakamura E, Sugihara H, Bamba M, Hattori T: Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas. J Pathol; 2005 Feb;205(3):349-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas.
  • To examine qualitative alterations of the E-cadherin/catenin complex (CCC) during cell differentiation and invasion of undifferentiated-type gastric carcinoma, immunoreactivity for the intracytoplasmic domain and the extracellular domain (ECD) of E-cadherin, and that of beta-catenin, was analysed in the mucosal, submucosal, and deepest invasive parts of 20 early and 20 advanced cancers that had a component of intramucosal signet ring cell carcinoma.
  • The tumours with a tubular component and without organized differentiation of signet ring cells in a layered structure were associated with nuclear expression of beta-catenin and may derive from tubular adenocarcinomas through de-differentiation and de-regulation of the Wnt pathway.
  • On the other hand, the tumours with a layered structure, which may derive from signet ring cell carcinoma by de novo abnormality of E-cadherin, were characterized by dynamic alteration of ECD expression during cell differentiation and tumour progression; intramucosal spread (with a layered structure) as well as deep invasion (beyond the submucosa) commonly showed cellular dissociation with downregulation of ECD, whereas submucosal invasion and lymph node metastasis often showed cellular cohesion and retention (or 'reappearance') of ECD.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Signet Ring Cell / metabolism. Cytoskeletal Proteins / metabolism. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Female. Gastric Mucosa / pathology. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. beta Catenin

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682444.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


82. Pavić I, Marusić Z, Mijić A, Balicević D, Kruslin B, Tomas D: A case of signet-ring cell carcinoma of the gallbladder: immunohistochemistry and differential diagnosis. Acta Clin Croat; 2010 Jun;49(2):159-62
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of signet-ring cell carcinoma of the gallbladder: immunohistochemistry and differential diagnosis.
  • The morphological spectrum of gallbladder carcinoma is broad and variable.
  • Most of these tumors are tubular adenocarcinomas.
  • One of such tumors is the signet-ring cell carcinoma, which is a highly aggressive, mucin producing variant of gallbladder adenocarcinoma predominantly or exclusively composed of signet-ring cells.
  • Histologically, these tumors are similar to their counterparts in other organs such as stomach, colon and breast, and should not be misinterpreted as metastatic carcinoma from one of these primary sites.
  • The literature about this variant of carcinoma is sparse and little is known about it.
  • We found only three cases of signet-ring cell carcinoma of the gallbladder previously reported.
  • We present the case of an 86-year-old woman with signet-ring cell carcinoma of the gallbladder and discuss the potential diagnostic dilemmas
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Gallbladder Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086733.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


83. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Yanaga K: Predictors for postoperative liver metastasis in patients with resectable pancreatic cancer. Int Surg; 2008 Nov-Dec;93(6):324-30
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although postoperative liver metastasis for pancreatic adenocarcinoma is a major problem that directly influences patient outcome, there is no useful predictor reported to date.
  • We reviewed 174 surgically resected pancreatic tubular adenocarcinomas for their clinicopathological data and time for the appearance of postoperative liver metastasis to occur, using the Cox proportional hazards model.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085041.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


84. Tanaka K, Toyoda H, Kadowaki S, Kosaka R, Shiraishi T, Imoto I, Shiku H, Adachi Y: Features of early gastric cancer and gastric adenoma by enhanced-magnification endoscopy. J Gastroenterol; 2006 Apr;41(4):332-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Changes to the mucosal surface of early gastric carcinomas and gastric adenomas as viewed by enhanced-magnification endoscopy with acetic acid have not been investigated thoroughly.
  • METHODS: Forty-seven consecutive patients with early gastric carcinomas or gastric adenomas underwent enhanced-magnification endoscopy following 1.5% acetic acid instillation.
  • Elevated carcinomas showed type III (42.9%) or type IV (57.1%) surface patterns, while depressed carcinomas showed type IV (70%) or type V (30%).
  • Although differentiated tubular adenocarcinomas showed type III (10.3%), type IV (86.2%), or type V (3.5%) surface patterns, all of the signet-ring cell carcinomas and poorly differentiated tubular adenocarcinomas showed type V.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Endoscopy, Gastrointestinal / methods. Image Enhancement. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Neoplasm Staging. Prospective Studies. Video Recording

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2006 Apr;41(4):397-8 [16741625.001]
  • (PMID = 16741612.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Izumi S, Nakamura S, Mano S, Suzuka I: Resection of four synchronous invasive ductal carcinomas in the pancreas head and body associated with pancreatic intraepithelial neoplasia: report of a case. Surg Today; 2009;39(12):1091-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of four synchronous invasive ductal carcinomas in the pancreas head and body associated with pancreatic intraepithelial neoplasia: report of a case.
  • This report describes a very rare case of four synchronous invasive ductal carcinomas (IDCs) in the pancreas head and body with possible multicentricity.
  • Histologically, the discontinuity between the four tumors was confirmed; one tumor (20 mm) was moderately differentiated tubular adenocarcinoma, and the others (25 mm, 10 mm, and 10 mm) were papillary adenocarcinomas.
  • Two smaller papillary adenocarcinomas were composed of abundant fibrosis, pancreatic intraepithelial neoplasia (PanIN) 2-3, and IDC with stromal invasion.
  • The immunohistochemical staining by CK20, MUC1, and Ki-67 revealed apparently different features for 2 IDCs (25 mm and 20 mm) and somewhat differential features for three papillary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasm Invasiveness / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997809.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S, Baba H, Yamamura K: Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res; 2009 Sep;7(9):1572-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first showed that SPINK1 induced proliferation of NIH 3T3 cells and pancreatic cancer cell lines.
  • To determine which pathway is the most important for cell growth, we further analyzed the effect of inhibitors.
  • To further analyze the clinical importance of SPINK1 in the development of pancreatic cancer, we examined the expression of SPINK1 and EGFR in pancreatic tubular adenocarcinomas and pancreatic intraepithelial neoplasm.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Growth Processes / drug effects. Cell Line, Tumor. Fibroblasts / drug effects. Humans. Immunohistochemistry. MAP Kinase Signaling System / drug effects. Mice. NIH 3T3 Cells. Phosphorylation / drug effects


87. Yoshimura A, Sugihara H, Ling ZQ, Peng DF, Mukaisho K, Fujiyama Y, Hattori T: How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas: analyses of intratumoral heterogeneity in deletion and mutation of TP53. Pathobiology; 2006;73(1):40-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas: analyses of intratumoral heterogeneity in deletion and mutation of TP53.
  • OBJECTIVE: In undifferentiated-type gastric carcinoma (UGC), inactivation of TP53 is infrequent at early stages and comparable to tubular adenocarcinomas (TUBs) at advanced stages.
  • METHODS: We used 27 UGCs including 12 mixed types with minor tubular component (TC) and 16 with a layered structure (LS), a histological remnant of incipient signet ring cell carcinoma (SIG).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Genes, p53. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785766.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


88. Murakami Y, Uemura K, Sasaki M, Morifuji M, Hayashidani Y, Sudo T, Sueda T: Duodenal cancer arising from the remaining duodenum after pylorus-preserving pancreatoduodenectomy for ampullary cancer in familial adenomatous polyposis. J Gastrointest Surg; 2005 Mar;9(3):389-92
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the current admission, the patient was diagnosed with adenocarcinoma in the Vater's ampulla using imaging and pathological examinations.
  • The tumor was a well-differentiated tubular adenocarcinoma and no other polyps were identified in the duodenum by pathological examination.
  • This lesion was completely resected by endoscopic mucosal resection and the resected specimen revealed well-differentiated tubular adenocarcinoma in an adenomatous lesion.
  • [MeSH-major] Adenocarcinoma / surgery. Adenomatous Polyposis Coli / secondary. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / secondary. Duodenal Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749602.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezón T, Friis E, Rank F: Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett; 2006 May 22;580(12):2935-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
  • Breast cancer is a heterogeneous disease that encompasses a wide range of histopathological types including: invasive ductal carcinoma, lobular carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma, and apocrine carcinoma among others.
  • Pure apocrine carcinomas represent about 0.5% of all invasive breast cancers according to the Danish Breast Cancer Cooperative Group Registry, and despite the fact that they are morphologically distinct from other breast lesions, there are at present no standard molecular criteria available for their diagnosis.
  • In addition, the relationship between benign apocrine changes and breast carcinoma is unclear and has been a matter of discussion for many years.
  • These biomarkers in combination with proteins found to be characteristically upregulated in pure apocrine carcinomas (psoriasin, S100A9, and p53) provide a protein expression signature distinctive for benign apocrine metaplasias and apocrine cystic lesions.
  • These studies have also presented compelling evidence for a direct link, through the expression of the prostaglandin degrading enzyme 15-PGDH, between early apocrine lesions and pure apocrine carcinomas.
  • Moreover, specific antibodies against the components of the expression signature have identified precursor lesions in the linear histological progression to apocrine carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631754.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 85
  •  go-up   go-down


90. Wu YL, Zhang S, Wang GR, Chen YP: Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol; 2008 Aug 21;14(31):4943-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion.
  • AIM: To investigate the relation of expression transformation of claudin-1 with invasiveness and metastasis of gastric carcinoma.
  • METHODS: By using immunohistochemistry, expression of claudin-1 in mucosa and invasive front of 136 gastric adenocarcinoma cases and proliferative index (Ki-67) were detected and analyzed.
  • RESULTS: In mucosa, the claudin-1 over-expression rate of mucinous adenocarcinomas (including signet-ring cell carcinomas) was the highest.
  • In invasive front, the claudin-1 over-expression rate was positively related with the differentiation, invasiveness and metastasis of gastric carcinoma.
  • The expression transformation of claudin-1 was found in gastric carcinoma.
  • The expression of claudin-1 in invasive front was transformed in 28/136 gastric carcinoma cases.
  • The transformation rate in highly differentiated tubular adenocarcinomas was the highest (51.5%, 17/33).
  • CONCLUSION: Up-regulation of claudin-1 expression and its transformation in invasive and metastatic gastric carcinoma suggest that claudin-1 participates in the transformation of biological behaviors in neoplasms.
  • [MeSH-major] Adenocarcinoma / chemistry. Gastric Mucosa / chemistry. Membrane Proteins / analysis. Stomach Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Proliferation. Claudin-1. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1999 Dec 13;147(6):1351-63 [10601346.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):511-8 [15475928.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):249-56 [11071387.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93 [11283726.001]
  • [Cites] J Cell Biol. 2001 Apr 16;153(2):263-72 [11309408.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28204-11 [11382769.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26233-40 [15905176.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):886-92 [16112005.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Virchows Arch. 2006 Jan;448(1):52-8 [16220299.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):280-4 [16875629.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):967-78 [12196510.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1959-67 [12668723.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Mar;22(1):117-23 [12725331.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):683-9 [12736707.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):275-88 [14567987.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):374-83 [14648703.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):159-64 [14991532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4690-4 [15070779.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Jun;30(6):761-70 [14656746.001]
  • [Cites] Exp Cell Res. 2004 Oct 15;300(1):202-12 [15383327.001]
  • [Cites] Annu Rev Physiol. 1998;60:121-42 [9558457.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):12725-31 [9582296.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 27;259(1):103-7 [10334923.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1567-74 [15547692.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] EMBO J. 2000 May 2;19(9):2024-33 [10790369.001]
  • (PMID = 18756604.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2739949
  •  go-up   go-down


91. Natsagdorj L, Sugihara H, Bamba M, Hattori T: Intratumoural heterogeneity of intestinal expression reflects environmental induction and progression-related loss of induction in undifferentiated-type gastric carcinomas. Histopathology; 2008 Dec;53(6):685-97
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoural heterogeneity of intestinal expression reflects environmental induction and progression-related loss of induction in undifferentiated-type gastric carcinomas.
  • METHODS AND RESULTS: We immunohistochemically examined intratumoural heterogeneity in the expression of Cdx2, MUC2, MUC5AC and MUC6 in 39 intramucosal and 49 extramucosally invasive undifferentiated-type gastric carcinomas (UGCs), consisting of signet ring cell carcinomas showing a layered structure (LS) in the mucosa and dedifferentiated tubular adenocarcinomas without LS and with minor tubular components (TC).
  • [MeSH-major] Carcinoma / metabolism. Carcinoma / pathology. Intestines / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Environment. Gene Expression. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Middle Aged. Mucin 5AC / genetics. Mucin 5AC / metabolism. Mucin-2 / genetics. Mucin-2 / metabolism. Mucin-6 / genetics. Mucin-6 / metabolism. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102008.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6
  •  go-up   go-down


92. Matsuda N, Saiki M, Kamihira S, Kanaoka Y, Ishiguro S, Ohgi S: Resection of a cardiac tumor extending into the inferior vena cava presenting as Budd-Chiari syndrome. Jpn J Thorac Cardiovasc Surg; 2006 Jul;54(7):285-8
MedlinePlus Health Information. consumer health - Heart Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report describes the successful treatment of a case of cardiac adenocarcinoma with the clinical presentation as Budd-Chiari syndrome.
  • Histopathological diagnosis of this tumor was tubular adenocarcinoma with positive immunostaining by carcinoembrionic antigen.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / surgery. Budd-Chiari Syndrome / etiology. Cardiac Surgical Procedures. Heart Neoplasms / complications. Heart Neoplasms / surgery. Vena Cava, Inferior / surgery

  • Genetic Alliance. consumer health - Budd-Chiari Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898641.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


93. Oo KZ, Xiao PQ: Infiltrating syringomatous adenoma of the nipple: clinical presentation and literature review. Arch Pathol Lab Med; 2009 Sep;133(9):1487-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringomatous adenoma of the nipple is often misdiagnosed because clinical examination and mammographic findings of syringomatous adenoma of the nipple mimic carcinoma.
  • Histologically and clinically, syringomatous adenoma of the nipple is often confused with tubular carcinoma as well as low-grade adenosquamous carcinoma of the breast.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722761.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


94. Rong ZX, Fang CH, Zhu DJ, Liu SJ: [Expression of Smo protein and the downstream transcription factor Gli1 protein in Sonic hedgehog signal transduction pathway in gastric carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec;26(12):1728-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Smo protein and the downstream transcription factor Gli1 protein in Sonic hedgehog signal transduction pathway in gastric carcinoma].
  • OBJECTIVE: To study the expression of Smo protein and the downstream transcription factor Gli1 protein in Sonic hedgehog signal transduction pathway in gastric carcinoma.
  • METHODS: A tissue microarray was constructed using 85 gastric carcinoma and 25 normal gastric mucosa specimens.
  • The expression of Smo and Gli1 proteins were detected immunohistochemically and the correlation between their expression in gastric carcinoma was analyzed.
  • RESULTS: Only weak expression, if any, of Smo and Gli1 proteins was detected in normal gastric mucosa, but in papillary adenocarcinoma, tubular adenocarcinoma and poorly differentiated adenocarcinoma, their expressions were significant increased as the differentiation degree was lowered.
  • Smo protein expression in gastric carcinoma was significantly correlated with that of Gli1 protein with correlation coefficient of 0.989 (P<0.001).
  • CONCLUSION: The abnormal activity of Sonic hedgehog signal transduction pathway may play an important role in the occurrence of papillary adenocarcinoma, tubular adenocarcinoma and poorly differentiated adenocarcinoma, and this abnormality is associated with Smo protein overexpression, which upregulates the expression of the downstream transcription factor Gli1 protein.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259107.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / Transcription Factors
  •  go-up   go-down


95. Hirakawa H, Nakayama T, Shibata K, Sekine I: Association of cellular localization of glycogen synthase kinase 3beta in the digestive tract with cancer development. Oncol Rep; 2009 Sep;22(3):481-5
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In normal simple columnar epithelium, GSK-3beta was localized with tight junction-associated protein ZO-1 in a single line at the apical cell border.
  • GSK-3beta and ZO-1 were localized in the apical regions of tubular adenocarcinoma, similar to their localization in normal epithelium; however, their localization was different at the invasive front of the cancer and was found to be associated with lymphatic invasion.
  • In signet-ring cell carcinoma of the stomach, the expression of these proteins was reduced and dot-like expression was observed in each cell of the signet-ring cell carcinoma.
  • We speculated that GSK-3beta is involved in glandular structure formation and that the non-apical localization of membrane-localized GSK-3beta in tubular adenocarcinoma is associated with cancer development.
  • [MeSH-minor] Adenocarcinoma / enzymology. Aged. Female. Genes, APC. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Male. Membrane Proteins / analysis. Middle Aged. Phosphoproteins / analysis. Zonula Occludens-1 Protein

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639192.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  •  go-up   go-down


96. Grieco V, Locatelli C, Riccardi E, Brambilla P: A case of two different tumors in the heart of a dog. J Vet Diagn Invest; 2008 May;20(3):365-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 9-year-old, spayed, female Maremmano shepherd had a bilateral mastectomy for multiple mammary adenocarcinomas 2 years previous and was referred to the Cardiology Service of the School of Veterinary Medicine of Milan after an acute episode of cardiogenic collapse.
  • Histological examination revealed the coexistence of tubular adenocarcinoma and an undifferentiated sarcoma in the myocardium.
  • To the authors' knowledge, this is the first report describing cardiac sarcoma of presumptive myofibroblastic origin in a dog with simultaneous occurrence of cardiac metastasis of mammary gland adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / diagnosis. Heart Neoplasms / veterinary. Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460629.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ: The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol; 2006 Jun;32(5):502-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
  • AIM: To report the incidence and predictive value of positive axillary nodes in ductal carcinoma in situ (DCIS) and T1a carcinoma of the breast.
  • Patients were identified with pure DCIS (n = 71), DCIS with small invasion (n = 12), invasive ductal/lobular carcinoma (IDC/ILC) < or =5 mm (n = 18) or tubular carcinoma < or =10 mm (n = 17).
  • In IDC/ILC sized 2-5 mm the incidence rose from 6 to 12% and in tubular carcinoma < or =10 mm from 0 to 12%.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / secondary. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Axilla. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Node Excision. Lymph Nodes / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Retrospective Studies. Sentinel Lymph Node Biopsy. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569492.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Liao J, Seril DN, Lu GG, Zhang M, Toyokuni S, Yang AL, Yang GY: Increased susceptibility of chronic ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 deficient mice. Mol Carcinog; 2008 Aug;47(8):638-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased susceptibility of chronic ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 deficient mice.
  • To elucidate the mechanistic role of inflammation-caused oxidative stress in carcinogenesis, the development of chronic ulcerative colitis (UC)-induced carcinoma in Ogg1 knockout mice was studied using a dextran sulfate sodium (DSS)-induced UC model without the use of a carcinogen.
  • In wild type C57BL/6 control mice after 15 cycles of DSS treatment, colorectal adenocarcinoma incidence was 24.1% (7/29 mice), with a tumor volume of 27.9 +/- 5.2 mm(3).
  • Ogg1 (-/-) mice showed significantly increased adenocarcinoma development in the colon with a tumor incidence of 57.1% (12 of 21 mice, P < 0.05) and a tumor volume of 35.1 +/- 6.1 mm(3).
  • Histopathologic analyses revealed that colorectal tumors were well-differentiated tubular adenocarcinomas or mucinous carcinoma and adjacent colonic mucosa showed mild to moderate chronic UC.

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1459-63 [11532868.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5378-81 [11454679.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;68:193-205 [11554297.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1266-78 [12064801.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):993-1001 [12082021.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Natl Cancer Inst. 1981 Mar;66(3):579-83 [6162992.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] N Engl J Med. 1987 Jun 25;316(26):1654-8 [3295551.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):694-702 [1688816.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4 [2154753.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Am J Surg. 1992 Jul;164(1):13-7 [1626600.001]
  • [Cites] Free Radic Biol Med. 1992;13(2):169-81 [1355459.001]
  • [Cites] Gut. 1992 Nov;33(11):1521-7 [1333439.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):189-95 [8342999.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1890s-1894s [8137306.001]
  • [Cites] Lancet. 1994 Sep 24;344(8926):859-61 [7916405.001]
  • [Cites] Lancet. 1995 Feb 18;345(8947):448; author reply 449 [7853963.001]
  • [Cites] Free Radic Biol Med. 1995 Apr;18(4):807-13 [7538480.001]
  • [Cites] Int J Biochem Cell Biol. 1995 Feb;27(2):109-22 [7767779.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5258-65 [7777494.001]
  • [Cites] Am J Clin Nutr. 1996 Jun;63(6):985S-990S [8644698.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6314-22 [9321410.001]
  • [Cites] Biochemistry (Mosc). 1997 Dec;62(12):1341-7 [9481868.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):9-16 [9511847.001]
  • [Cites] Scand J Gastroenterol. 1998 Feb;33(2):164-9 [9517527.001]
  • [Cites] Am J Physiol. 1998 Mar;274(3 Pt 1):G544-51 [9530156.001]
  • [Cites] Dig Dis Sci. 1998 May;43(5):1088-95 [9590426.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):711-21 [9635855.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13300-5 [10557315.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):757-68 [10753213.001]
  • [Cites] Histopathology. 2001 Sep;39(3):221-34 [11532032.001]
  • (PMID = 18300266.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104741-04; United States / NCI NIH HHS / CA / R01 CA104741; United States / NCI NIH HHS / CA / R01 CA104741-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / Ogg1 protein, mouse; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ NIHMS45508; NLM/ PMC2752943
  •  go-up   go-down


99. Ueda J, Aimoto T, Nakamura Y, Hiroi M, Yamahatsu K, Hayakawa T, Naito Z, Uchida E: [Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma]. Nihon Shokakibyo Gakkai Zasshi; 2010 Dec;107(12):1941-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma].
  • Although as duodenal GIST was diagnosed, histologic examination for frozen sections during the procedure revealed tubular adenocarcinoma of the duodenum and pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma.
  • Clinicopathologically, the neuroendocrine carcinoma of the pancreaticoduodenal lymph node was considered to be metastasis from an unknown primary lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Neuroendocrine / secondary. Duodenal Neoplasms / pathology. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139363.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Yamato H, Kawakami H, Kuwatani M, Shinada K, Kondo S, Kubota K, Asaka M: Pancreatic carcinoma associated with portal vein tumor thrombus: three case reports. Intern Med; 2009;48(3):143-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic carcinoma associated with portal vein tumor thrombus: three case reports.
  • Pancreatic carcinoma associated with portal vein tumor thrombus (PVTT) is rare.
  • Here, we report three cases of resected pancreatic carcinoma associated with PVTT.
  • The pathological diagnoses of the tumors were two cases of tubular adenocarcinoma and one case of nonfunctioning endocrine carcinoma.
  • [MeSH-major] Carcinoma / pathology. Pancreatic Neoplasms / pathology. Portal Vein / pathology. Thrombosis / pathology

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19182424.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down






Advertisement